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Abstract 
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Abstract 
Ficolins are members of the collectin family of proteins which in human and mice are able to 
recognize pathogen associated molecular patterns (PAMPs) on microbial surfaces. Ficolins 
trigger the activation of the innate immune system by initiating the complement cascade in 
serum upon binding to their specific PAMPs. Our group recently published the first 
observation on the cellular localization of mouse ficolin-B. In contrast to the human ortholog 
M-ficolin which is secreted, ficolin-B was only detected intracellularly in peritoneal 
macrophages (Runza et al., 2006). Investigations on the expression profile in our laboratory 
indicated that ficolin-B expression is down-regulated upon maturation of myeloid cells such 
as macrophages, granulocytes, and bone marrow-derived dendritic cells suggesting a critical 
role of ficolin-B during early stages of cell activation upon pathogen encounter. In contrast to 
others who have shown that ficolin-B does not associate to serine proteases and, therefore, 
is unable to activate the complement system (Endo et al., 2005) unpublished findings by our 
group show complement activation by ficolin-B. However, the biological relevance of these 
findings and the function of mouse ficolin-B upon bacterial challenge remains to be 
elucidated.  
An established method for the recombinant production of ficolin-B in an eukaryotic (insect) 
expression (DS2 cells) system exists in our lab. This method is, however, expensive and 
time consuming. The first goal of this work was to establish an alternative expression system 
in E.coli to produce recombinant ficolin-B without tag. The biological activity of the E.coli-
expressed ficolin-B was to be compared to the activity of the DS2-expressed ficolin-B. The 
protein should then be used to immunize rats to generate monoclonal antibodies. 
In the second part of the project functional characterization of ficolin-B through mutational 
analysis should be tested. Ficolin-B muteins are expected to define the differences in fine 
specificity as shown by Xenopus, mouse, and human ficolins and, as such, bring evidence 
for adaptive changes during evolution. Ficolin-B has a conserved collagen binding site (Girija 
et al., 2007) that has been linked to important functions such as lectin pathway activation and 
collaboration with the blood coagulation system by interacting with serine proteases like 
MASPs (Endo et al., 2010). Weak adjacent sites of the MASP binding domain may enhance 
or decrease affinity for binding, but little is known about the biological role of this affinity 
modulation. The aim was to alter the biological activity of ficolin-B by introduction of a single 
amino acid mutation in the collagen like domain. Protein biochemical and chromatographic 
studies were performed to compare the ficolin-B wild type and mutant forms.…………........ll
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Zusammenfassung 
Ficoline sind Mitglieder der Collectin-Proteinfamilie, die in Mensch und Maus Pathogen-
assoziierte molekulare Muster (PAMP) auf Oberflächen erkennen. Ficoline starten das 
angeborene Immunsystem, indem sie im Serum nach Bindung an spezifische PAMP die 
Complement-Kaskade aktivieren. Unsere Arbeitsgruppe zeigte als erste, dass Maus-Ficolin-
B intrazellulär lokalisiert ist. Im Gegensatz zum humanen Ortholog, M-Ficolin, wurde Ficolin-
B nur intrazellulär in Peritonealmakrophagen nachgewiesen (Runza et al., 2006). 
Untersuchungen zum Expressionsprofil aus unserem Labor zeigten, dass Ficolin-B während 
der Reifung myeloider Zellen, wie Makrophagen, Granulozyten und vom Knochenmark 
abgeleiteten Dendritischen Zellen, herunterreguliert wird, was für eine wichtige Funktion von 
Ficolin-B in den frühen Stadien der Zellaktivierung nach Pathogen-Kontakt spricht. Ebenfalls 
im Gegensatz zu Befunden anderer Gruppen, die zeigten, dass Ficolin-B nicht mit 
Serinproteasen assoziiert und daher unfähig ist das Complementsystem zu aktivieren (Endo 
et al. 2005), finden wir eine Aktivierung des Complementsystems durch Ficolin-B 
(unveröffentlicht). Die biologische Bedeutung dieser Befunde und die Funktion von Maus-
Ficolin-B nach bakterieller Belastung müssen jedoch noch geklärt werden. 
Eine Methode zur Produktion von rekombinantem Ficolin-B in Insekten(DS2)-Zellen ist in 
unserem Labor etabliert. Die Methode ist jedoch teuer und langwierig. Das erste Ziel dieser 
Arbeit war es, ein alternatives Expressionsystem in E. coli zu etablieren, um rekombinantes 
Ficolin-B ohne Tag zu produzieren. Die biologische Aktivität des E. coli-exprimierten Ficolin-
B sollte mit der Aktivität von DS2-Zellen-exprimiertem Ficolin-B verglichen werden. Das 
Protein selbst sollte zur Immunisierung von Ratten zur Herstellung monoklonaler Antikörper 
dienen. 
Im zweiten Teil des Projektes sollte Ficolin-B funktionell durch Mutations-Analyse 
charakterisiert werden. Ficolin-B-Muteine könnten Spezifitätsunterschiede erklären, wie 
schon für adaptive Veränderungen während der Evolution durch Vergleich von Xenopus-, 
Maus- und Mensch-Ficolin-B-Ortholog geschehen. Ficolin-B hat eine konservierte Collagen-
Bindungsstelle (Girija et al., 2007), die mit den wichtigen Funktionen wie Lektinweg-
Aktivierung und Interaktion mit dem Gerinungssystem durch Interaktion mit Serinproteasen 
wie MASP verknüpft ist (Endo et al., 2010). Schwache benachbarte Bindungsstellen der 
Bindungsstelle können die Affinität erhöhen oder erniedrigen, wobei wenig über die 
biologische Rolle dieser Affinitätsmodulation bekannt ist. Durch Mutation einer einzigen 
Aminosäure in der Collagen-Bindungsstelle von Ficolin-B sollte die biologische Aktivität 
verändert werden. Biochemische und chromatographische Untersuchungen sollten 
durchgeführt werden, um Wild-Typ- und Mutein-Ficolin-B zu vergleichen. 
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1. Introduction 
1.1. The immune system 
The immune system is a complex network of cells, tissues, and organs that work together to 
defend the body against any “foreign” invaders. These are primarily microbes—tiny 
organisms such as bacteria, parasites, and fungi that can cause infections. The human body 
provides an ideal environment for many microbes. It is the immune system’s job to attack 
and wipe out nearly all of them.  
This is done in two ways: The adaptive or acquired immunity, consisting of B and T cells, 
uses a vast set of antibodies and T cell receptors with a high specificity against any foreign 
components. The highly effective acquired immunity is responsible for elimination of infection 
in a late phase and for the establishment of immunological memory. By contrast, the innate 
immune system constitutes the first-line of host defence in the early phase of infection.  It 
recognizes only a limited number of conserved structures of invading microorganisms 
through a limited number of germline encoded receptors and it seems to be independent of 
immunologic memory (Akira et al., 2006). Furthermore, innate immunity provides co-
stimulatory molecules and cytokines to direct the adaptive immune response. 
1.1.1. Overview of the innate immune system 
The immune system consists of a diverse but interconnected group of defence mechanisms 
that prevent an individual from infection and disease (Jeanne Kelly, NIH publication No. 07-
5423, sept. 2007). Many of these constituents are present from birth or act without the need 
for prior exposure to foreign material. These include physical barriers like the skin and 
mucous membranes, production of antimicrobial compounds and cellular killing processes. 
Collectively these mechanisms are defined as innate immunity and share certain 
characteristics that differentiate them from acquired immunity, the other main branch of the 
immune system.  
 “Innate immunity is evolutionary ancient” (Agrawal, 1998). The innate immune response, 
phylogenetically conserved and present in almost all multicellular organisms, is the first line 
of host defence and is responsible for immediately recognizing and countering microbial 
invasion (Hoffmann et al., 1999). This arm of the immune system is comprised mainly of 
complement proteins, phagocytic cells such as macrophages and neutrophils, which can 
ingest and kill the invading pathogens. These cells can also instruct the adaptive immune 
response about the nature of the pathogenic challenge through cytokine and chemokine 
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production, expression of costimulatory molecules, and presentation of microbial antigens to 
lymphocytes leading to the development of a highly specific adapative immune response. 
Mutations in innate immunity genes are usually lethal. In comparison, acquired immunity is 
slower to develop but is required for the removal of pathogens that have evolved to evade 
the innate response (Schatz et al., 1992). Through somatic rearrangement of antigen 
receptor genes, the adaptive immune system is capable of recognizing an unlimited variety 
of proteins and carbohydrates. However, without underlying innate immunity, these 
processes are ineffective.  
The main distinction between these is the receptor types used to recognize pathogens 
(Ruslan Medzhitov, 2007). Innate immune recognition is mediated by pattern recognition 
receptors (PRRs), which are germline encoded, and each receptor has broad specificities for 
conserved and invariant features of microorganisms (Janeway, 1989). By contrast, adaptive 
immune recognition is mediated by antigen receptors: the genes encoding these receptors 
are assembled from gene segments in the germ line, and somatic recombination of these 
segments enables the generation of a vast diverse collection of receptors with random but 
narrow specificities (Schatz, 1992). 
1.1.2. Recognition of microorganisms by the innate immune system  
Whenever a microorganism is able to cross the epithelium, myeloid cells, located in the 
submucosal tissues, are the first cells to encounter the pathogens, and they are soon 
strengthend by the recruitment of large numbers of neutrophils to the site of infection 
(Janeway, Jr. and Medzhitov, 2002). Macrophages and neutrophils, both phagocytes, 
recognize microorganisms by means of their cell-surface receptors that can discriminate 
between self and non-self. These receptors include the mannose receptor (only on 
macrophages), scavenger receptors, which bind negatively charged ligands such as 
lipoteichoic acids (LTA, cell-wall components of Gram-positive bacteria), and CD14, a 
receptor for lipopolysaccharides (LPS, cell-wall component of Gram-negative bacteria) (Feizi, 
2000). Upon ligation of many of these receptors  pathogen binding will result in phagocytosis. 
Phagocytosis is an active process in which the bound pathogen is first surrounded by the 
phagocyte membrane and then internalized in a membrane-bound vesicle known as the 
phagosome, where the microbe is killed by acidification of the vesicle. In addition, 
macrophages and neutrophils also possess vacuoles called lysosomes that contain 
enzymes, proteins, and peptides that can mediate intracellular killing of the bacteria. The 
phagosome fuses with one or more lysosomes to generate a phagolysosome in which the  
lysosomal contents are released to destroy the pathogen. During phagocytosis, 
macrophages and neutrophils produce toxic products like nitric oxide (NO), the superoxide 
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anion (O2-), and hydrogen peroxide (H2O2) that helps kill microorganisms (Janeway, Jr. et al., 
2005). The interaction between pathogens and tissue macrophages leads to release of 
cytokines, chemokines (chemotactic cytokines), and other mediators that attracts neutrophils 
and other cells to the site of infection. Furthermore, it stimulates the expression of co-
stimulatory molecules (i.e. B7.1/CD80 and B7.2/CD86) on macrophages and on dendritic 
cells to intiate an adaptive immune response (Janeway, Jr. and Medzhitov, 2002). 
1.1.3. Toll-like receptors: discriminating ‘self’ from ‘non-self’   
Toll-like receptors (TLR) are membrane-bound proteins that activate a leukocyte when bound 
to its ligands. (Akira et al., 2006) TLRs widely recognize viral nucleic acids and several 
bacterial products, including lipopolysaccharide and lipoteichoic acids. Currently there are 10 
known human TLRs (Lichtman, 2003). Although they may share a similar function in 
immunity, the TLRs vary in cellular expression, ligand specificity, cellular location, and 
adapter molecules (Ishii, 2008). Toll-like receptor ligands are primarily pathogen associated 
molecular patterns (PAMPs). These molecules are structures that are evolutionary 
conserved in many different pathogens. For example, TLR4 recognizes lipopolysaccharide 
(LPS) a common surface molecule of Gram-negative bacteria, fungal mannans, and viral 
envelope proteins (Fig 1.1). TLR3 recognises viral double-stranded RNA, TLR4 LPS, TLR5 
flagellin and TLR9 bacterial CpG DNA. With the exception of TLR3, TLRs induce nuclear 
factor (NF)-kB-dependent expression of proinflammatory and immunoregulatory genes via a 
common signaling adaptor, the myeloid differentiation primary-response protein 88 (MyD88). 
However, TLR3, as well as TLR4, upon endocytosis into endosomes, can signal through the 
Toll/IL-1R(TIR)-domain-containing adapter inducing IFN-β (TRIF) pathway, that triggers 
activation of the interferon regulatory factor-3 (IRF-3) and type I interferon production (O’Neil, 
2008). When bound, the ligand receptor complex recruits signaling proteins and initiates 
signalling cascades (e.g., NF-κB or MAPK) which leads to the transcription and expression of 
a wide range of inducible proteins such as inflammatory cytokines (TNF), chemokines (IL-8), 
or costimulatory molecules (CD80) which coordinates local and systemic inflammatory 
responses (Blander, 2008). Furthermore, IL-1β, together with IL-6, activates hepatocytes to 
produce acute phase proteins, including collectins and pentraxins. These proteins, in turn, 
activate complement and opsonize pathogens for phagocytosis by macrophages and 
neutrophils. In this way, TLRs indirectly elicit an antimicrobial response. 
In addition to TLRs, there are several other classes of pattern recognition receptors. The 
family of nucleotide-binding oligomerization domain (NOD)-like receptors, unlike TLRs, is 
cytoplasmic and is capable of sensing PAMPs created by viruses (Iwasaki, 2009) or 
intracellular bacteria. 
1. Introduction 
4 
 
              Figure 1.1 | Major forms of TLRs and their specific ligands.(Lambris, 2010) 
1.2. The complement system 
The complement system is the central component of the innate immune system comprising 
of at least 35 proteins which collaborate in an intricate manner in the elimination of 
microorganisms and in the removal of apoptotic cells, but also serves as a natural adjuvant, 
enhancing and directing the adaptive immune response (Walport, 2001). 
There are three major pathways of complement activation, namely, the classical pathway 
which is activated by certain isotypes of antibodies bound to antigens; the alternative 
pathway which is activated on microbial cell surface in the absence of antibody and the lectin 
pathway which is activated by plasma lectins that bind to carbohydrate residues on microbes. 
MBL and ficolins are the complement-activating PRM which act via the lectin pathway. 
In the following sections, the activation, regulation, and biological effects of the complement 
system will be described. 
1.2.1. Complement intiation and amplification 
The classical pathway (CP) starts when C1q binds to the pathogen surface. The binding of 
this molecule to a microorganism can occur in three different ways. First, it can bind directly 
to bacterial surface components such as certain proteins of the cell wall and polyanionic 
surface structures (i.e. LTA on Gram-positive bacteria). Second, C1q can bind to the C-
reactive protein, which is a human plasma protein with specificity for phosphocholine 
residues in bacterial polysaccharides (i.e. the pneumococcal C polysaccharide). Third, as a 
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linker between the innate and the adaptive immune systems, C1q binds to the Fc domains of 
antibody:antigen complexes (Arlaud et al., 2002). C1q is part of the C1 complex which has a  
single C1q molecule bound to two molecules of zymogens C1r and C1s (Janeway CA Jr, et 
al.,2001). C1q is a calcium-dependent sugar-binding protein, which has six globular heads, 
linked together by a collagen-like tail, which surround the (C1r:C1s)2 complex. Binding of 
more than one of the C1q heads to a pathogen surface causes a conformational change in 
the (C1r:C1s)2 complex, which leads to activation of an autocatalytic enzymatic activity in 
C1r; the active form of C1r then cleaves its associated C1s to generate an active serine 
protease. Activated C1r then activates C1s, which in turn cleaves C4 and C2 to generate C3 
convertase C4b2a. This consequently leads to the activation of the central component of 
complement C3. The generated C3b opsonizes pathogens to facilitate their elimination by 
phagocytosis, and the generated convertases C4b2a and C3bBb activate C5 on pathogens, 
inducing the lytic pathway via the late components of complement, C5 to C9. 
In the lectin pathway (LP), MBL and ficolins serve as recognition molecules against 
pathogens which are molecules similar to C1q. While activated MASP-2, which is one of 
three human MASPs (MASP-1, MASP-2 and MASP-3) and a main effector of the lectin 
pathway, activates C4 and C2 to generate C3 convertase C4b2a, like C1s in the classical 
pathway (Matsushita et al., 2000b; Rossi et al., 2001) (Fig. 1.2). It was reported that MASP-1 
activates MASP-2 (Takahashi et al., 2008). MASP-1 also activates factor D, which is an early 
component of the alternative pathway, suggesting that MASP-1 is an initiator of the 
alternative pathway (Takahashi et al., 2010). MASPs, C1r and C1s are each members of the 
MASP/C1r/C1s family, a subfamily of the serine protease superfamily (Endo et al., 1998, 
2003). Thus the lectin pathway initiates complement activation in a way similar to the 
classical pathway, forming a C3 convertase from C2b bound to C4b (Janeway, Jr. et al., 
2005). 
The third pathway, alternative pathway (AP) of the complement system is independent of 
the presence of antibodies and activated by different molecules and pathogens including 
gram negative bacteria and cell wall of gram positive bacteria (Pangburn and Muller-
Eberhard 1984). The spontaneous hydrolysis of C3 which is also known as the “tickover” 
leads to the formation of C3i. The C3i acts as a binding site for Factor B which is cleaved by 
Factor D to form Ba (small fragment of Factor B). The initial convertase, C3(H2O)Bb, is 
highly unstable and is able to cleave C3 to C3a and C3b. If present, C3b binds to an 
activating surface. Together with Factor B and Factor D, the complex C3bBb is produced and 
is stabilized by binding of Properdin to form the C3 convertase (C3iBb). This creates an 
amplification loop to generate more C3 convertase. C3b can bind to the C3 convertase to 
produce C5 convertase which can cleave C5 to C5a and C5b. C5b can bind to C6-9 to 
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produce the membrane-attack complex (MAC) leading to the lysis of target cell. The MAC is 
intiated by enzymatic cleavage of C5 and then leads to the sequential binding of C6, C7, C8 
and C9. Several C9 molecules bind to the C5b678 complex, producing the pore channel, 
MAC. Once MAC forms into the cell or pathogen membrane, this will lead to cell lysis due to 
the formation of ion-permeable pores or channel or leaky patches (Muller-Eberhard 1986; 
Morgan 1999).  
 
 
Fig. 1.2 | A schematic representation of the three pathways of complement activation: 
The classical, alternative and lectin pathways. The classical pathway is initiated by the binding 
of the C1 complex to antibodies that are bound to antigens on the surface of bacteria. The 
lectin pathway is initiated by the binding of either mannose-binding lectin (MBL) or ficolin — 
associated with MBL-associated serine protease 1 (MASP1), MASP2, MASP3 and small MBL-
associated protein (sMAP) — to an array of carbohydrate groups on the surface of a bacterial 
cell. The alternative pathway is initiated by the low-grade activation of C3 by hydrolysed C3 
(C3(H2O)) and activated factor B (Bb). Red arrows depict the activation reactions (Endo, 
2011).  
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1.2.2. Effector functions of complement  
When PAMPs are detected on invading microorganisms, one or several complement 
initiation pathways that aim to eliminate microbial intruders are triggered. The complement 
cascade leads to the formation of the MAC on the pathogen surface which finally leads to the 
eventual destruction of the pathogen (Parker and Sodetz, 2002; Janeway, Jr. et al., 2005). In 
addition to the MAC formation, all along the cascade the complement generates large 
numbers of activated proteins that either opsonize the pathogen or act as chemotactic 
molecules. Acute-phase proteins increases markedly at the early stage of infection and key 
components of this response is the secreted PRRs: collectins, ficolins and pentraxins. They 
activate the complement system by opsonising microbial cells for phagocytosis. Collectins 
and ficolins activate the lectin pathway of the complement system (Endo et al., 2006; 
Holmskov et al., 2003), whereas, pentraxins activate the classical pathway (Bottazi et al., 
2006). 
C3a and especially C5a are strong chemoattractants that guide neutrophils, monocytes and 
macrophages towards sites of complement activation and promote phagocytosis through 
interaction with opsonins (Ricklin et al., 2010). There are various complement receptors 
(CRs) that act as opsonins. Among these receptors, CR1 (CD35), is expressed on 
macrophages and polymorphonuclear lymphocytes (PMNs), and can bind to C3b, C4b and 
iC3b (Whaley and Schwaeble, 1997) to promote neutrophil-mediated phagocytosis and 
regulatory degradation of its ligands by factor I (fI) (Atkinson et al., 2001). CR2 (CD21) is 
found on B cells as part of a co-receptor for B-cell activation and differentiation and also 
binds to the inactive forms of C3b, C3dg that remain attached to the pathogen surface 
(Whaley and Schwaeble, 1997). CR3 (CD11b:CD18), and CR4 (CD11c:CD18) are integrin 
receptors that binds iC3b fragment and contributes to phagocytosis. CR3 also regulates 
cytokine responses, leukocyte trafficking and synapse formation.   
C3a, C4a, and C5a are small complement fragments that act on specific receptors to 
produce local inflammatory responses (Janeway CA Jr, Travers P, Walport M, et al. 2001). 
When produced in large amounts or injected systemically, they induce a generalized 
circulatory collapse, producing a shocklike syndrome similar to that seen in a systemic 
allergic reaction involving IgE antibodies. Such a reaction is termed „anaphylactic shock” and 
these small complement fragments are therefore often referred to as anaphylatoxins. Of the 
three, C5a is the most stable and has the highest specific biological activity. All three induce 
smooth muscle contraction and increase vascular permeability. C3a and C5a are constantly 
released and trigger proinflammatory signaling through their corresponding G-protein–
coupled receptors, C3a receptor (C3aR) and C5a receptor (C5aR; also called CD88). A third, 
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G-protein–independent anaphylatoxin receptor, C5L2 (GPR77), has more recently been 
discovered. However, its exact roles are not yet fully determined (Ward, 2009). 
In summary, the changes induced mainly by C5a and C3a recruit antibodies, complement 
components, and phagocytic cells to the site of infection leading to defence aganist microbial 
intruders. 
1.2.3. Complement regulation 
Soluble and cell-bound complement regulators play a major role in complement regulation 
and help to control complement attack (Zipfel, 2009; Fig. 1.3). C1 esterase inhibitor (C1-
INH), a secreted glycoprotein of the serpin family that inhibits several proteases of the 
classical and lectin pathways, In addition to that, two other lectin pathway modulators have 
been identified: sMAP and MAP-1 are nonproteolytic splice products of the MASP2 and 
MASP1/3 genes, respectively, that apparently compete with MASPs for binding to MBL and 
ficolins. The C2 receptor inhibitor also binds to C2 and inhibits its activation by C1s (Skerka, 
2009). In the alternative pathway, activation in solution is mainly controlled by the abundant 
factor H (fH) and its truncated homolog, factor H-like protein 1 (FHL-1). fH mainly acts on C3 
convertases in the alternative pathway, either competitively removing Bb from the C3bBb 
complex (decay acceleration) or serving as a cofactor for the factor I (fI)-mediated 
degradation of C3b. Another fluid-phase regulator, C4b-binding protein (C4BP), has similar 
effects on classical pathway and lectin pathway convertases. Most importantly, fH, FHL-1 
and C4BP also support complement regulation on human cells by engaging host-specific 
surface patterns (such as sialic acid or glycosaminoglycans), thereby contributing to self-
recognition and prevention of self-attack. On the other hand, during complement activation, 
some C5b67 complexes gets deposited on nearby cells which leads to cell lysis. To prevent 
this, cell-based regulators like Clusterin bind to C5b67 which prevent insertion of the complex 
to the membrane (Tschopp and French 1994). Protectin or CD59 inhibits insertion and 
unfolding of C9 into membranes. Vitronectin inhibits the membrane-damaging effect of TCC. 
Most human cells also expose convertase regulators (membrane regulators) that act as 
decay accelerators, such as CR1 or decay-accelerating factor (DAF, also called CD55), or as 
cofactors for fI, such as CR1 and membrane cofactor protein (MCP or CD46) (Jalali, 2010). 
Only a few C5-specific regulators have been described so far; whereas fH-related protein 1 
directly binds C5 and inhibits C5 convertase activity, CRIg regulates the C3b-containing C3 
and C5 convertases, although the physiological implications of this mechanism are unknown. 
Finally, carboxypeptidase-N quickly converts anaphylatoxins to their desarginated 
forms;C3adesArg and C5adesArg and they can trigger important functions like hematopoietic 
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stem-progenitor cell (HSPC) mobilization (Ratajczak, 2006) or lipid metabolism (Mclaren, 
2008). 
 
          Figure 1.3 | Immune regulation functions of complement. (Lambris, 2010) 
1.2.4. Complement in health and diseases 
Besides the more ‘classical’ roles of complement in the elimination of microbial intruders and 
clearance of apoptotic debris, complement has important roles in cell homeostasis and 
disease. In Alzheimer’s disease, both C1q abd C3 recognize accumulating amyloid fibrils and 
induce activation of complement. In sepsis (Fig.1.4a), microorganisms poison the blood and 
cause excessive complement activation with release of C5a that contributes to severe effects 
like immune depletion to severe inflammation and disseminated coagulation, all of which may 
result in tissue damage, multi-organ failure and death (Ward, 2004). Complement has a role 
in synaptogenesis (Fig. 1.4b), where it eliminates weak or immature synapses. “An unknown 
signal derived from immature astrocytes promotes recognition by C1q, which leads to 
opsonisation with C3b and iC3b and facilitates complement receptor (CR)-mediated 
phagocytosis by activated microglia” (Schafer et al., 2010). Although the role of the C5L2 
receptor in the immune response is unclear, it seems to play a vital role in lipid metabolism 
(Fig. 1.4c). Adipocytes secrete C3, fB and fD, and this expression can be promoted by stimuli 
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such as insulin or lipids, leading to a higher turnover of the alternative pathway and 
generation of C3a, which is transformed into the C3adesArg fragment (ASP). This fragment 
can induce lipid clearance, glucose uptake and triglyceride (TG) synthesis in adipocytes 
through C5L2 signaling. Complement is likely to have a dual role in cancer (Fig. 1.4d): It 
contributes to protection through direct activation of complement or as part of the 
complement-dependent cytotoxicity of tumor-directed therapeutic antibodies (Lambris et al., 
2009). However, many tumors escape complement attack by expressing and secreting 
complement inhibitors that largely prevent amplification, TCC formation or complement-
mediated phagocytosis. The generation of C5a in the tumor microenvironment can attract 
myeloid-derived suppressor cells (MDSC) and induce the generation of reactive oxygen and 
nitrogen species (ROS and RNS, respectively) through the C5a receptor (C5aR), which 
impairs the tumor-directed effect of T cells (Markiewski et al., 2008). 
The deficiency of classical pathway C proteins will lead to SLE. Patients with C-deficiencies 
are at particular risk of developing serious infections with encapsulated organisms such as 
S.pneumoniae and Neisseria meningitides.  
The deficiency of lectin pathway results from low concentrations of MBL and has been 
associated with an increased risk, severity and autoimmune disorders (Sorensen et al., 
2005) and increased susceptibility to fungal, protozoal and viral infections (Hajela et al., 
2008). MBL deficiency has also been associated with infections of the respiratory tract 
(Eisen, 2010) and with increased disease severity in cystic fibrosis (Fidler et al., 2009). MBL 
deficiency is one of the most common human immunodeficiencies and arises primarily from 
three single point mutations in exon 1 of the MBL-2 gene. This mutations result in a failure to 
assemble fully functional multimeric protein (Turnet, 2003). To date, clinical studies have 
shown that MBL deficiency predispose to infectious diseases such as pneumococcal 
infection (Eisen, 2010). 
The deficiency of the alternate pathway is due to the components which include fB, factor D, 
properdin and C3. Meningococcal infections have been seen in multiple individuals Neisseria 
meningitides as the most common pathogen encountered. Factor I deficiency has been 
associated with glomerulonephritis with reduced levels of CR1 expression (Ponce et al., 
2001). General deficiencies of C5, C6, C7, or C8 lead to increased suspetibility to 
meningococcal infections. C9 individuals have some haemolytic and bactericidal activity, but 
they are still predisposed to meningococcal infections (Nagata et al., 1989). 
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Figure 1.4 | Emerging roles of complement in health and disease. Role of complement (a) 
in sepsis b) in synaptogenesis (c) in lipid metabolism (d) a dual role in cancer (Lambris, 2010). 
 
To date no ficolin deficiencies have been reported. However studies on L-ficolin 
polymorphisms have been reported (Hummelshoj et al., 2005; Herpers et al., 2005), and it 
shows that these genetic variations are associated with both the serum levels and the N-
acetyl-D-glucosamine (GlcNAc) binding activity. It was reported that low L-ficolin is 
associated to prematurity, low birth weight and infection in neonates (Swierzko et al., 2008), 
allergic rhinitis (Cedzynski et al., 2009), and severe streptococcal infection (Messias-Reason 
et al., 2009). Low H-ficolin deficiency is associated with recurrent infection (Munthe-fog et al., 
2009), fever and neutropenia (Schlapbach et al., 2010). 
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1.3. Lectins – “The Pattern recognition molecule” 
Lectins are carbohydrate-binding proteins that play an important role in innate immunity by 
recognizing a wide range of pathogens and by aggregating and opsonising them. This 
recognition is mediated by a set of pattern-recognition receptors (PRR) that recognize 
conserved pathogen-associated molecular patterns (PAMPs) shared by broad classes of 
microorganisms, thereby successfully discriminating pathogens from self. PAMPs are 
essential for the survival of certain microbial groups, and are, therefore, highly conserved 
among the different classes of pathogens (Medzhitov and Janeway, Jr., 2000b). Lectins form 
a class of PRRs that bind specifically to the unique carbohydrate moieties on microbes (Lu et 
al., 2002). Among the lectins known, MBL and ficolins are the typical pattern recognition 
proteins. 
1.3.1. Mannose binding lectin (MBL) 
MBL consists of large oligomers assembled from identical polypeptide chains (Drickamer and 
Taylor, 1993). Three polypeptide chains assemble into structural subunits, which associate 
into higher oligomeric forms. Each subunit is composed of an N-terminal  cysteine-rich 
domain followed by a collagenous domain, an α-helical coiled coil or neck region and three 
C-terminal C-type carbohydrate-recognition domains (CRDs) which is the ligand binding 
domain (Fig.1.5). The N-terminal cysteine rich region is stablized by hydrophobic interaction 
and interchain disulphide bonds. In serum, MBL consists of oligomers of the trimeric subunit, 
ranging from dimers to hexamers. MBL of higher order oligomers (e.g. tetramers to 
hexamers) are necessary for stable binding of MBL to pathogens which leads to effective 
forms of the protein functions, for examples, the glycan interaction and complement 
activation on microbial surfaces (Kawasaki et al., 1995). 
MBLs recognise foreign cells via multivalent interactions with the carbohydrate epitopes 
commonly found on pathogens. Each CRD has a single binding site for monosaccharides 
such  as  mannose,  fucose or N-acetylglucosamine, which occur only rarely at the terminal 
positions of mammalian oligosaccharides on glycoproteins and glycolipids but are present in  
high-density arrays on many bacterial, fungal and parasitic cells (Drickamer, 1993). 
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Fig. 1.5 | Domain organisation of MBL (A) Structural organisation of MBL. Each subunit has 
N-terminal cys-rich region, middle collagen-like domain and c-terminal darbohydrate 
recognition domain. The MASPs binding site resides in the collagen domain. Arrows show 
potentially flexible regions (Wallis, 2007) (B) Single polypeptide chain (C) the basic structure 
subunit of MBL formed by three polypeptide chains  (D) MBL oligomers formed by multiple 
subunits (Stuart et al., 2009). 
There are two human MBL genes but MBL-1 is a pseudogene and only MBL-2 encodes a 
protein product. In rodents two MBL genes are expressed, namely MBL-A and MBL-C. It has 
been shown that MBL is an acute phase protein that increases in serum levels following 
infection and trauma (Thiel et al., 1992). Liver is the main site for MBL biosynthesis, but its 
expression is also seen in other tissues of mouse (Uemura et al., 2002; Wagner et al., 2003). 
The average median concentration of MBL in plasma is around 1.5µg/ml and this 
concentration varies to a large degree in every individuals due to polymorphisms in the  
promoter region and in exon 1 of the gene (reviewed in Turner et al., 2000, Garred et al., 
2006). MBL has been shown to bind to a wide range of micro-organisms (Neth et al., 2000) 
and further interaction with MASPs leads to the activation of the lectin pathway of the 
complement system. 
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1.3.2. Ficolins 
Ficolins are a group of oligomeric lectins which are able to recognize pathogen-associated 
molecular patterns (PAMP) on microbial surfaces. Upon binding to their specific PAMP, 
ficolins may trigger activation of the complement system via the lectin pathway. Ficolins were 
first identified as transforming growth factor-β1 (TGF-β1)-binding proteins on pig uterus 
membranes (Ichijo et al., 1991). Their primary structure revealed that they are mainly 
composed of fibrinogen- and collagen-like domains and, this unique feature gave them their 
name ficolins (Ichijo et al., 1993). It was demonstrated that all ficolins (except mouse ficolin-
B) can associate with MASPs and small MBL-associated protein (sMAP), suggesting they 
play a role in the complement activation through the lectin pathway (Matsushita et al., 2000a, 
2002; Liu et al., 2005a).  
 
Table 1 - Characteristics of ficolins 
                  (Matsushita, 2010) 
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There are two types of ficolin present in each species, a serum type (or plasma type) and a 
non-serum type (or non-plasma type) (Endo et al., 2007). The former is expressed mainly in 
the liver and is present in the circulation as a serum lectin, including human L-ficolin and H-
ficolin, M-ficolin (Garred et al., 2008), mouse ficolin-A and porcine ficolin - α. While the latter 
is expressed mainly in non-liver tissues, such as peripheral leukocytes and bone marrow, 
including human M-ficolin, mouse ficolin-B and porcine ficolin-β. To date, the ficolin 
homologues (Table 1) have been isolated from human (Endo et al., 1996, Lu et al., 1998) 
and non-human vertebrate species such as mice (Fujimori et al., 1998; Ohashi and Erickson, 
1998), hedgehog (Omori-Satoh et al., 2000) and Xenopus (Kakinuma et al., 2003), and also 
from an invertebrate species, ascidian (Halocynthia roretzi)(Kenjo et al., 2001).  
 
1.3.2.1. Characteristics of human and mouse ficolins 
1.3.2.1.1. Structure, expression, and location of human ficolins 
There are three types of human ficolins known, L, H, and M. From a structural point of view, 
ficolins are assembled from basal homotrimeric subunits comprising a collagen-like triple 
helix and a globular recognition domain composed of 3 fibrinogen-like domains (fig.1.6). Two 
cysteines at the N-terminal end of the polypeptide chains form interchain disulfide bonds that 
mediate assembly into higher oligomeric structures. Like MBL, ficolins are able to trigger the 
complement cascade through activation of the serine protease MASP-2 (Fujita et al., 2001). 
The MASP interaction site within the collagen-like regions of human MBL and ficolins has 
been recently mapped and shown to have a conserved lysine residue (Girija et al., 2007). 
The fibrinogen-like domain is globular, and the overall structure of L-ficolin resembles a 
“bouquet”. The proposed structure is a tetramer consisting of 4 triple helices formed by 12 
subunits (Garred et al., 2007). There is one potential N-linked glycosylation site in the 
fibrinogen domain and five potential O-linked sites in the collagen-like domain (Wallis et al., 
2011). 
H-Ficolin was first identified as a serum antigen recognized by an autoantibody present in 
patients with systemic lupus erythematosus matosus (Inaba et al., 1978). H-ficolin is an 
oligomer of 34-kDa subunits (Yae et al., 1991). The H-ficolin gene (FCN3) is located on 
chromosome 1p35.3 and consists of 8 exons with similar organization as the L-ficolin gene. 
H-ficolin mRNA is expressed in the liver and lung. In the liver, H-ficolin is produced by bile 
duct epithelial cells and hepatocytes and is secreted into bile and serum (Akaiwa et al., 
1999). In the lungs, H-ficolin is produced by both ciliated bronchial epithelial cells and type II 
alveolar epithelial cells and is secreted into the bronchus and alveolus. H-ficolin mRNA 
expression was found in human glioma cell line T98G (Kuraya et al., 2003).  
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A)   Structural organization of ficolins
C) D)
B)
Collagen stalk
Basic structural unit - Trimer Oligomer (4 to 6 Trimers)
Trimeric
fibrinogen-like Domain
Cys-rich domain
Fig. 1.6 | Structural organization of ficolins and their multivalent recognition function. A) 
Each mature polypeptide chain comprises a cysteine-rich N-terminal sequence (black), a 
collagen-like sequence (hatched), a linker segment (white) and a fibrinogen-like sequence 
(purple). The N-linked oligosaccharides ( ♦ ), the binding site for the MASPs ( ∗ ) and the 2 N-
terminal cysteine residues are indicated. B) X-ray structure of the fibrinogen-like protomer. 
Domains A, B and P are colored red, green and blue respectively. The N-terminal disulfide 
bond (S-S) is shown in red. A Ca 2+ ion is represented by a yellow sphere. (Garlatti et al., 
2010). C) Monomeric subunits assemble to form the trimer via the collagen-like domain.D) 
Four to six trimers assemble the multimer (Oligomer), potentially by crosslinking via disulfide 
bridges in the N-terminal region (Endo et al., 2011). 
The mRNA of M-ficolin is expressed in monocytes, lungs, and the spleen (Lu et al., 1996). 
The M-ficolin gene (FCN1) is located on chromosome 9q34. M-ficolin has an extra exon 
encoding an additional segment of 4 Gly-Xaa-Yaa repeats. M-ficolin has been reported to be 
expressed on the surface of peripheral blood monocytes and pro-monocytic U937 cells (Teh 
et al., 2000). M-ficolin is a secretory protein and it has been found to be located in secretory 
granules in the cytoplasm of peripheral neutrophils and monocytes and in type II alveolar 
epithelial cells in the lungs (Liu et al., 2005). Recent report has shown that M-ficolin is 
present in human plasma at very low levels (Garred et al., 2008).  
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L-Ficolin is an oligomeric protein consisting of 35-kDa subunits (Mizuochi et al., 1998). Two 
cysteine residues in the N-terminal domain are thought to mediate multimerization by 
disulfide bonding. The L-ficolin gene (FCN2) is located on chromosome 9q34 and contains 8 
exons (Fujita et al., 1996). The mRNA of L-ficolin is mainly expressed in the liver and its 
protein product is secreted into serum. 
 
1.3.2.1.2. Expression and location of mouse ficolins  
Mice have 2 types of ficolins, termed ficolin-A and ficolin-B. The ficolin-A gene was first 
isolated from a mouse liver library (Fujimori et al., 1998). Both ficolin-A and ficolin-B genes 
are located on chromosome 2A3. Ficolin-A is the plasma protein with a molecular mass of 37 
kDa, highly expressed in liver and spleen (Fujimori et al., 1998). The ficolin-A protein is 
present as a tetramer with 12 subunits (Ohashi et al., 1998). Ficolin-A mRNA is expressed 
during ontogenesis as early as on embryonic day (E) 12.5, displaying an increase in 
abundance during development, peaking around birth, and slightly declining in the adult 
stages (Liu et al., 2005a). In addition, In situ hybridization studies indicated that ficolin-A 
mRNA was mainly localized in the linings of the hepatic sinusoids in the liver, and in the red 
pulp of the spleen. These observations suggest that ficolin-A mRNA is expressed by cells of 
the monocyte-macrophage lineage (Liu et al., 2005a). 
Ficolin-B was first characterized by Ohashi and Erickson in 1998 with strong mRNA 
expression in bone marrow and weak expression in spleen. The expression of ficolin-B in the 
liver increases with development, peaks two or three days before birth, and thereafter rapidly 
declines to an undetectable level. Thus, the expression of ficolin-B switches from the 
embryonic liver to postnatal bone marrow and spleen. The different spatial–temporal 
expression patterns suggest that ficolin-A and ficolin-B might play distinct roles during the 
prenatal and postnatal stages (Liu et al., 2005). Our group (Runza et al., 2006) recently 
published the first observation on ficolin-B expression at the protein level. Ficolin-B was 
found to be expressed by peritoneal macrophages of C57Bl/6 mice by immunocytochemistry, 
and surprisingly a positive staining was detected only after permeabilization of the cells 
indicating an intracellular expression and not a cell-association of this protein. Recently, it 
has been demonstrated that mouse ficolin-A and ficolin-B show lectin activities for GlcNAc 
and GalNAc, and like human M-ficolin, ficolin-B additionally recognizes sialic acid residues 
inthe sugar chain (Endo et al., 2005). The binding-specificity of M-ficolin and ficolin-B to sialic 
acid residue suggests a unique role for non-serum type ficolin. 
 
 
1. Introduction 
18 
Sequence alignments reveal that (Lys55) which is a conserved residue in the collagen domain 
of MBL is also conserved in ficolins and plays a critical role by forming the key contacts with 
the MASP-2 binding (Lacroix et al., 2008) and the adjacent residues mainly methionine or 
alanine might help to stabilize the interaction (Girija et al., 2007). Although mouse ficolin-B 
possesses a similar binding motif, it is unusual compared to other ficolins because it contains 
an acidic residue adjacent to the key conserved lysine: Hyp-Gly-Lys-Glu-Gly-Pro. This 
adjacent glutamic acid residue is likely to disrupt MASP binding and activation, explaining the 
lack of complement activation by mouse ficolin-B (Girija et al., 2011). 
 
 
Fig. 1.7 | Two routes of ficolin function: The human ficolins and mouse ficolin-A execute 
their functions through the lectin pathway, while mouse ficolin-B does through its strong 
agglutination activity. The existence of the latter route is supported by observation that ficolin-B 
aggregates bacteria stronger than ficolin-A leading to enhanced phagocytosis of the 
aggregated bacteria by mouse peritoneal macrophages (Endo et al., 2007). 
Interestingly, the recombinant mouse ficolin-B, but not ficolin-A, had a strong activity to 
aggregate Staphyloccus aureus which leads to phagocytosis of the bacteria by mouse 
peritoneal macrophages without involvement of serum components (Endo et al., 2007). This 
result suggests that ficolin has two distinct ways to eliminate pathogens: one is a classical 
route through the lectin pathway executed by human ficolins and mouse ficolin-A, the other is 
a primitive opsonophagocytosis executed by mouse ficolin-B (Fig. 1.7) (Endo et al., 2007). 
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1.3.2.2. Functions of ficolins 
1.3.2.2.1.  Carbohydrate and pathogen recognition of ficolins 
The fibrinogen-like domains of ficolin are responsible for carbohydrate and pathogen 
recognition. X-ray crystallography studies on ficolins demonstrated the molecular basis of 
GlcNAc-recognition in the fibrinogen-like domains (Garlatti et al., 2007a, 2007b; Tanio et al., 
2007). In L-ficolin, four ligand binding sites S1 to S4 were identified (Fig 1.8) (Garlatti et al., 
2007a). The Ca2+ is bound to the loop region located adjacent to the ligand-binding site. 
However, it remains controversial as to whether this recognition requires Ca2+ or not 
(Ohashi and Erickson, 1997). (Matsushita et al., 1996; Endo et al., 2006) reported that the 
binding of L-ficolin to GlcNAc requires Ca2+. The four ligand-binding sites provide a 
continuous recognition surface, which can detect various acetylated and neutral 
carbohydrates on microbes. The binding sites can be abolished by EDTA and sodium 
acetate (Lacroix et al., 2009). The S1 binding site gets disrupted and exhibits increased 
flexibility at acidic pH (Tanio et al., 2006). 
 
Fig. 1.8 | The ligand binding sites in M- and L-ficolins. A) An outer binding site (S1) 
showing the binding regions for GlcNAc, GalNAc and Neu5Ac, on each protomer of the 
trimeric fibrinogen-like domain of M-ficolin. B) Three binding sites S2, S3, and S4  were 
observed in the trimeric fibrinogen-like domain of L-ficolin, which binds to a wide variety of 
acetylated ligands and some neutral sugars (galactose,  β-D-glucan) (Garalatti., 2010). 
L-ficolin binds to GlcNAc-BSA and complex-type oligosaccharide chains with GlcNAc linked 
to the trimannosyl core (Matsushita et al., 1996).  L-ficolin can bind specifically to lipoteichoic 
acid (LTA), a cell wall constituent of Gram-positive bacteria (Lynch et al., 2004). It also binds 
to peptidoglycan, a component of the bacterial cell wall, and 1, 3-β-D-glucan, a component of 
Ca2+
A B
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yeast and fungal cell walls (Ma et al., 2004). L-ficolin binds to Gram-positive bacteria such as 
serotype III group B streptococci, Strept. pneumoniae 11F and S. aureus, and to Gram-
negative bacteria such as E. coli and S. typhimurium, TV119 (Matsushita et al., 1996; Krarup 
et al., 2003; Aoyagi et al., 2005). L-ficolin was shown to enhance the uptake of S. 
typhimurium strains by neutrophils, suggesting that it serves as an opsonin for phagocytosis 
(Matsushita et al., 1996). It was also demonstrated that L-ficolin recognizes DNA, which 
enables the binding of L-ficolin to late apoptotic and necrotic cells (Jensens et al., 2007). 
The recombinant M-ficolin binds to GlcNAc-BSA, N-acetylgalactosamine (GalNAc)-BSA and 
sialyl N-acetyllactosamine- BSA (Liu et al., 2005a). Specific binding to sialic acid was 
confirmed by the binding of M-ficolin to the glycoprotein fetuin, and not to its asialo derivative 
(Liu et al., 2005). M-ficolin has been found on the surface of monocytes and U937 cells (Teh 
et al., 2000). M-ficolin binds to S. aureus and S. typhimurium LT2 (Liu et al., 2005a). 
H-ficolin also binds to GlcNAc and GalNAc, but not to mannose and lactose (Sugimoto et al., 
1998). H-ficolin-induced agglutination of human erythrocytes, coated with 
lipopolysaccharides (LPS) derived from S. typhimurium, S. minnesota and E. coli (O111), 
was inhibited by GlcNAc, GalNAc and fucose (Misao et al., 2002). H-ficolin binds neither 
S.aureus nor S. pneumoniae, but can bind to Aerococcus viridans, and inhibits its growth 
(Tsujimura et al., 2002). 
The mouse ficolin-A and ficolin-B also bind to GlcNAc and GalNAc, and ficolin-B, like M-
ficolin, additionally recognizes sialic acid residues (Endo et al., 2005). Thus, all ficolins in 
common can recognize GlcNAc. All these observations show that, like MBL, ficolins play an 
important role in the clearance of both apoptotic cells and microorganisms. 
 
1.3.2.3. Ficolin complex formation with MASPs and sMAP 
Like MBL, all ficolins activate the lectin pathway in association with the key enzymes, MASPs 
(Matsushita et al., 2000a, 2000b, 2002; Liu et al., 2005a). The MASP and sMAP binding is 
mediated through the collagen region of ficolin (Lacroix et al., 2009). Upon binding of ficolin 
to ligands the associated MASP exhibit proteolytic activities and activates complement 
components. As shown in (Fig 1.9), the carbohydrate residue on the microbe is recognized 
and sensitizes the fibrinogen domain of ficolin. This leads to the activation of serine protease 
MASP2 and triggers complement components of lectin pathway. MASP-2 is the only MBL-
associated protease that efficiently can activate the complement cascade (Thiel et al., 1997).  
It was previously reported that unlike ficolin-A, mouse ficolin-B failed to form complexes with 
MASP-2 and sMAP (Endo et al., 2005). However, “it was recently reported that unlike mouse 
ficolin-B, rat ficolin-B associated to and activated MASP-2 (Girija et al., 2011). This result 
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might suggest that like the other mammalian ficolins, murine ficolin B also plays a role in the 
complex with MASPs in the lectin pathway” (Endo et al., 2011). 
 
 
Fig. 1.9 | Ficolin-MASPs/sMAP complex. The sugar residue on the microbe is recognized by 
the fibrinogen domain of ficolin and triggers the lectin pathway. The complexed MASPs are 
converted to the active forms and activates the lectin pathway of the complement system 
(Endo., 2007). 
 
1.3.2.4. Collaboration of ficolin with other defense systems 
Ficolins and MBL are higher oligomers composed of monomeric subunits and therefore have 
multivalent ligand-binding sites. Fibrinogen (Fbg) is a dimer of 3 subunits, formulated as 
(Aα)2(Bβ)2α2,  and fibrin (Fbn) is a polymer consisting of (α2, β2 , γ2 )n . The tetrapeptide 
GlyProArgPro, a known inhibitor of blood coagulation, mimics the N-terminal sequences of 
fibrin α- and β-chains.  Recently, Endo et al., (2010) confirmed that ficolin-A binds to the Aα- 
and Bβ-chains of fibrinogen and the α- and β-chains of fibrin, but not to the γ-chain, and that 
MBL preferentially binds to the fibrin α- and β-chains. Based on these observations, he 
suggested the hypothesis that ficolins can interact with fibrinogen and/or fibrin and the lectin 
pathway might collaborate with the coagulation system in the first-line host defence against 
pathogens. Ficolin or MBL bind to sugar residues on microbes at the ligand binding site and 
also bind to fibrinogen or fibrin with their remaining binding sites (Fig.1.10). Thrombin and 
MASP2 activate factor XIII to XIIIa and this leads to form a cross-link between fibrin and 
pathogen and within fibrin. This binding results in a complex network on the pathogen and 
activates MASP2 for further intiation of the downstream cascade of the lectin pathway. 
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Fig. 1.10 | A schematic model showing the collaboration of the lectin pathway with 
blood coagulation. (Endo.,et al  2011). 
It has also been shown that human C-reactive protein (CRP) can bind to S.enterica and L-
ficolin. This interaction between CRP and L-ficolin stabilizes the binding of CRP to the 
bacteria and increases complement activation (Ng et al., 2007; Zhang et al., 2009). This 
observation shows that the recognition molecule–pathogen complex is stabilized by another 
plasma protein and, in turn, this stabilization boosts the lectin pathway. Thus, it is suggested 
that the lectin pathway ‘cross talks’ and collaborates with other defense systems, such as 
blood coagulation and acute phase inflammation, to eliminate pathogens with high efficiency. 
1.3.3. Mannose binding lectin associated serine proteases (MASPs) 
MASPs are serine proteases that are activated when complexed with MBL. They cleave 
complement C4 and C2 to form C4b2a, the classical pathway C3 convertase (Matsushita 
and Fujita, 1992).  There are three known serine proteases, namely MBL-associated serine 
proteases (MASP-1, -2 and -3). A small non-enzymatic protein, MAp19 (or sMAP), is an 
alternatively spliced product which shares its origin with MASP-2 and another non-catalytic 
protein, MAp44 (or MAP1), which shares its origin with MASP-1 and MASP-3 (Garred et al., 
2010). MASPs are homodimers which are composed of a CUB domain at the N-terminal end 
followed by an epidermal growth factor (EGF) domain, a second CUB domain, two 
complement control protein (CCP) domains, and a serine protease domain (Fig. 1.11) 
(Wallis, 2002). Binding is mediated through a portion of the collagenous domain of MBL and 
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the N-terminal domains of the MASP. All three N-terminal MASP domains (CUB1–EGF–
CUB2) are necessary and sufficient to reproduce the binding properties of the full length 
proteins. The CUB1–EGF domains bind to MBL in a Ca2+ manner. 
 
A
 
                            Fig. 1.11 | Domain organisation of MASPs (Wallis, 2002) 
MASPs normally circulate as zymogens. However, when MBL/MASP or ficolin/MASP 
complexes bind to target epitopes on pathogens, MASPs-1 and -2 activate through autolysis 
at a single site within the short linker region between the CCP-2 module and serine protease 
domain. The active protease domain remains attached to the N-terminal fragment through a 
single disulphide bond. MASP-3 is also activated through cleavage of the linker region.  
However, the zymogen cannot auto-activate, it might be probably activated through an 
unidentified serum protease (Zundel et al., 2004). MASP-2 is the only MBL-associated 
protease that efficiently can activate the complement cascade (Thiel et al., 1997). MASP-1 
activates factor D, which is an early component of the alternative pathway, MASP-1 most 
likely enhances complement activation initiated by MASP-2 (Rossi et al., 2001). MASP-3 
shows no proteolytic activities and therefore is not directly involved in the initiation of the 
lectin pathway of complement (Zundel et al., 2004). On contrast, MASP-3 has been shown to 
down-regulate H-ficolin mediated complement activation (Skjoedt et al., 2009). MAp19 is an 
alternative splice product of the MASP-2 gene (Stover et al., 1999a; Stover et al., 1999b). It 
is found in association with MBL or in complex with MASP-1 in serum, but its physiological 
role has not been determined yet (Thiel et al., 2000). Another inhibitor Map44 was recently 
characterized as competing with MASP-2 for binding to ficolin and MBL resulting in inhibition 
of complement activation (Skjoedt et al., 2009). 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
Item                                          Manufacturer 
 
Agarose, electrophoresis grade Invitrogen 
Acetic acid AppliChem 
Acetone Merck 
Acrylamide/Bisacrylamide  Bio-Rad 
Ampicillin, >98% Sigma-Aldrich  
APS, ammonium persulfate Biorad 
Bromphenol Blue  Sigma-Aldrich 
BSA, bovine serum albumin, fraction V Biomol 
Calcium chloride Sigma-Aldrich 
Chloramphenicol Sigma-Aldrich 
Chelating Sepharose Fast Flow  GE Healthcare 
CNBr-activated Sepharose 4B GE Healthcare 
Coomassie Brilliant Blue R250 Fluka 
Deoxynucleotides, PCR grade Roche Applied Science 
DMEM medium Invitrogen 
DMSO, dimethyl sulfoxide Sigma-Aldrich  
Dried milk powder Nestlé 
Dithiothreitol NEB 
EDTA Sigma-Aldrich 
Eppendorf combitips Eppendorf 
Eppendorf tubes Eppendorf 
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Ethanol, abs. AppliChem 
Ethidium bromide Sigma-Aldrich 
FCS, fetal calf serum PAN Biotech 
Gentamycin PAA Laboratories 
Glutamine Biochrom AG 
Glutathione (Oxdised) Sigma-Aldrich 
Glutathione (Reduced) Sigma-Aldrich 
Glutathione Sepharose® 4B Amersham 
Glycerol, ultrapure Invitrogen 
Guanidine hydrochloride Sigma-Aldrich 
H2O (deionized) Milli Q UF Plus system 
HEPES Sigma-Aldrich 
Hygromycin-B Invitrogen 
IPTG, isopropyl-β-D-thiogalactoside  Biomol 
Kanamycin Invitrogen 
LB Broth Base Sigma-Aldrich 
Lysozyme Sigma-Aldrich 
ß-mercaptoethanol for cell culture Invitrogen 
ß-mercaptoethanol for molecular biology Sigma-Aldrich 
Methanol, technical grade Merck 
Magnesium chloride Sigma-Aldrich 
Ni-NTA (Nitrilotriacetic acid)  Agarose QIAGEN 
Nowa Solution A+B (ECL) MoBiTec 
Nuclease free water Promega 
PBS buffer (10X Dulbecco’s) powder Applichem 
Polyacrylamide, Rotiphorese® Gel30 (37,5:1) Carl Roth 
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Penicillin/Streptomycin Gibco 
Phenol/chloroform, for DNA purification Carl Roth 
PMSF Sigma-Aldrich 
2-Propanol  Merck 
RNAse A, DNAse free Roche Applied Science 
RPMI-1640 Sigma-Aldrich  
SDS ultra pure Sigma-Aldrich 
Sodium acetate Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium hydroxide Sigma-Aldrich 
SDS-PAGE Molecular weight standard, broad range  Biorad 
TEMED, Tetramethylethylenediamin  Biorad 
Triton X-100 GE Healthcare 
Tris Base Sigma-Aldrich 
Tryptone Difco 
TSR (Template suppression reagent) Applied Biosystems 
Tween 20 Fluka 
Urea Molecular Probes 
Whatman round filter Whatman 
X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactoside) Biomol 
Yeast extract Difco 
β-Mercaptoethanol  Sigma-Aldrich 
Aspergillus fumigatus from Prof. Dr. Frank Ebel, Max-von-Pettenkofer-Institut, München. 
Unless otherwise noted all the buffer-substances and chemicals were purchased from 
Sigma-Aldrich®, Fluka® or Applichem®. DNA-purification-Kits were purchased from 
QIAgen® and ProOmega. 
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2.1.2. Buffers and Solutions 
2.1.2.1. Acrylamide Gel electrophoresis (Protein SDS-PAGE) 
Separating Gel 
H2O dest 20.2 ml 17.1 ml 14.5 ml 12.3 ml 
3M Tris-HCl 
pH 9.0 
3.8 ml 3.8 ml 3.8 ml 3.8 ml 
Acrylamid Roti 
30 
6.8 ml 7.9 ml 10.5 ml 12.7 ml 
20% SDS 0.15 ml 0.15 ml 0.15 ml 0.5 ml 
TEMED 0.03 ml 0.03 ml 0.03 ml 0.03 ml 
10% APS 0.15 ml 0.15 ml 0.15 ml 0.15 ml 
 
Stacking Gel 
H2O dest 7.7 ml 
1M Tris-HCl pH 6.8 1.25 ml 
Acrylamid Roti 30 1.66 ml 
20% SDS 0.05 ml 
TEMED 0.015 ml 
10% APS 0.1 ml 
 
Blocking for Western Blot     5% Milk powder in TBS-T 
Blot buffer (Western blot)     190mM Glycine 
25 mM Tris base 
20% (v/v) Methanol 
Coomassie-Staining solution     10% Acetic acid 
40% Ethanol 
0,2% Coomassie Brilliant Blue 
R250 
 
6.5% 7.5% 10% 12% 
2. Materials and Methods 
 
28 
Coomassie-Destaining solution    10% Acetic acid 
40% Ethanol 
Blot stripping buffer      62.5mM Tris 
        2%SDS 
0.04% 2-Mercaptoethanol 
0.005 % Bromphenolblue 
DNA Loading Dye Solution (6x)     0.25% Bromphenolblue 
0.25% Xylencyanol 
30% Glycerol in H2O 
Electrophoresis buffer (10x)      25 mM Tris Base 
190 mM Glycine 
0.1% SDS at pH 8.6 
Gel filtration buffer       20mM Tris, pH 8.0 
50 mM KCl 
Lysis buffer (Protein)      10 mg/ml Lysozyme 
60 mg/ml Na-Desoxycholate 
1 M Mgcl2 
6 mg/ml DNaseI 
PBS         137 mM NaCl 
6.5 mM Na2HPO4 x H2O 
1.5 mM KH2PO4 
2.7 mM KCl 
PBS-T        0.05% Tween 20 in PBS-buffer 
Ponceau S       0.2% Ponceau S 
        3% Trichloroacetic acid 
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SDS-loading buffer (1x)     60mM Tris-HCL, pH 6.8 
        10% Glycerin 
        3% SDS 
        5% β-Mercaptoethanol 
                  0.005% Bromophenol blue 
TAE-buffer        40 mM Tris-Acetate 
1 mM EDTA 
TBS-buffer        8 g NaCl 
0.2 g KCl 
3 g Tris Base 
TBS-T        0.05 % Tween 20 in TBS-buffer 
Tris-buffer for SDS-PAGE      1,5 M Tris-HCl (pH 8.8) 
0.5 M Tris-HCl (pH 6.8) 
10x TBE buffer (DNA electrophoresis)   890 mM Tris 
        89 mM Boric acid 
        20 mM EDTA 
IMPACT Kit buffers 
Lysis buffer:       20 mM Tris-HCl, pH 8.5 
500 mM NaCl 
Column buffer       20 mM Tris-HCl, pH 8.5 
500 mM NaCl 
Cleavage buffer      20 mM Tris-HCl 
500 mM NaCl 
        50 mM DTT 
Stripping Solution      0.3 M NaOH 
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2.1.3. Analytical Kits 
 
BCA protein assay Kit Pierce, Rockford, IL, USA 
Dc Protein Assay Biorad 
Gel Extraction Kit QIAEX II QIAGEN 
HiFi PCR Master Kit Roche 
IMPACT™ Kit NEB 
pGEM – T –Easy vector system Promega 
Plasmid Purification Maxi Kit QIAGEN 
Plasmid Purification Mini Kit QIAGEN 
Prime-It® II Random Primer Labelling Kit Stratagene 
Reverse Transcription Kit Promega 
RNA Isolation Kit Macherey Nagel 
RNeasy Mini Kit QIAGEN 
RNase-free DNase Set QIAGEN 
TOPO TA Cloning® Kit Invitrogen 
Wizard®     SV gel and PCR clean-Up system    Promega 
Wizard® Plus Miniprep DNA Purification System Promega 
 
2.1.4. Standards 
Standards Manufacturer 
1 kb ladder for DNA NEB 
Kaleidoscope prestained standards Bio-Rad 
Precision Plus Protein dual color standards Bio-Rad 
Pre-stained Molecular Weight Standard Mixture for protein Fermentas 
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2.1.5. Enzymes 
 
Enzyme Manufacturer 
Calf Intestinal Phosphatase 
(CIP) NEB 
DNase I Sigma 
Endonucleases NEB and MBI-Fermentas 
Lysozyme Sigma-Aldrich 
Klenow fragment Roche 
M-MLV Reverse Transcriptase Promega 
Pfu DNA-Polymerase Promega 
Pfx DNA-Polymerase Invitrogen 
RNase A Roche 
T4 DNA ligase NEB 
Taq DNA-Polymerase peQLab 
 
2.1.6. Antibodies 
2.1.6.1. Primary antibodies 
Antibody/ Antigen  Species  Application Working 
Dilution 
Manufacturer 
Chicken anti-ficolin -
B (polyclonal) 
Chicken 
polyclonal 
WB 
1:2000 
GmBH Davids 
Biotech 
Anti chitin binding 
domain(monoclonal) 
Rabbit WB 1.2000 NEB 
Rabbit anti-ficolin-B 
(polyclonal) 
ELISA / WB / IP WB 1:2000 Lab source 
Rat anti-ficolin-B 
(monoclonal) IA4 
ELISA WB 1:500 Lab source 
Anti-GST / anti-GST  goat 
monoclonal  
WB 1:10000 Amersham,  
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2.1.6.2. Secondary antibodies 
Antibody/Antigen  Species  Application Working 
Dilution 
Manufacturer 
Anti-goat 
horseradish-
peroxidase linked  
sheep 
polyclonal  
WB 1:5000  Amersham, 
NA933  
Anti Chicken-IgY  Hen WB 1.3000 GmBH Davids 
Biotech 
Goat anti-rabbit-IgG-
HRP 
WB WB 1:1000 
 
Sigma 
Rat anti-ficolin-B 
(monoclonal) 
ELISA WB 1:500 
 
Lab source 
 
2.1.7. Expression vectors 
Plasmid  Annotation Marker  Supplier  
 
pTXB1 
 
vector for high–level expression of C–
terminally intein tagged proteins in 
bacteria 
Ampicillin NEB 
pGEX-4T-1 vector for high–level expression of C–
terminally GST–tagged proteins in 
bacteria  
Ampicillin  Pharmacia  
pGEX-4T-1-
N -TEV 
vector for high–level expression of C–
terminally GST–tagged proteins in 
bacteria with TEV site for cleavage 
Ampicillin  MPI, 
Dortmund 
 
pCR®2.1-
TOPO 
Vector with single 3’-thymidine overhangs 
for direct cloning of Taq-amplified PCR 
products 
Ampicillin  Invitrogen 
pMT/BiP/V5
-His A 
Vector includes the Drosophila 
metallothionein (MT) promoter for high- 
Level, copper-inducible expression. 
Ampicillin  Invitrogen 
 
pProEXHTb 
Bacterial expression vector, genes cloned 
into the MCS will be expressed as fusion 
proteins with an N-terminally 6xHis tag 
Ampicillin Invitrogen 
pET28 vector for high–level expression of N – 
terminal His tagged proteins in bacteria 
Kanamycin Novagen 
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2.1.8. Organisms and cell lines  
2.1.8.1. Bacterial strains 
Strains  Derivative Genotype Antibiotic 
resistance 
E.coli Dh5α  K12 F–,ø80dlacZ∆M15, ∆(lacZYA-argF)U169, 
deoR, recA1, endA1, hsdR17(rK–, mK+), 
phoA, supE44, λ–, thi-1, gyrA96, relA1  
Ampicilin 
BL21 (DE3) 
“Rosetta” 
BL21 F-ompT hsdSB(rB-mB-) gal dcm pRARE2 
(Camr) 
Chloramphenicol 
(34 µg/ml) 
BL21 (DE3) 
pLysS 
B 834 F- ompT hsdSB(rB –mB -) gal dcm (DE3) Chloramphenicol 
(34 µg/ml) 
TG1  K12 supE hsd∆5 thi ∆ (lac±proAB) F´[traD36 
proAB+lacIq lacZ∆M15] 
None 
OneShot®T
OP10F’ 
MC1061 mcrA(mrr-hsdRMS-mcrBC) 80lacZM15 
lacX74recA1araD139(ara-leu)7697galU 
galK rpsL (StrR) endA1 nupG 
Ampicilin 
XL-1 blue K12 recA1endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac {F´ proAB lacIqZ∆M15 Tn10 
(Tetr)} 
Tetracycline 
 
2.1.8.2. Cultured cell lines 
Cell line Medium and antibiotic 
resistance 
Annotation 
Drosophila Schneider 2 (S2) 
cell line 
Insect media (Insect X-press, 
Cambrex), kanamycin 
Derived from a primary 
culture of late stage  
Drosophila melanogaster 
embryos 
 
2.1.9. Oligonucleotides 
All primers used for cloning, sequencing or screening were purchased from Metabion at a 
concentration of 100 pmol/µl, and stored at -20°C in aliquots of 10 pmol/ µl until use.  
The primers used in this work are listed below: 
Primers Usage 5’  3’ Sequence 
Ficolin B  
Intein Nde 5´ 
Forward Primer 5´GGT GGT CAT ATG TGC CCA GAA CTG 
AAA GTC 
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Ficolin B  
Intein Sap 3´ 
Reverse primer 5´GGT GGT TCG TCT TCC GCA GAT GAG 
CCG CAC CTT CAT 
FicolinB-
BamHI-5´ 
Forward Primer 5´ CC GGA TCC ATG GCC CTG GGA TCT 
GCT TGC 
FicolinB-XhoI 
stop-3´ 
Reverse primer 5´ CC CTC GAG CAG AGA ACA AGC ACC 
TTT TGA AA 
FicolinB- 
XhoI- 5´ 
Forward Primer 5´ CC CTC GAG AGA GGA GAG AGT GGC 
C 
FicolinB-XhoI 
stop-3´ 
Reverse primer 5´ CC CTC GAG TTA GGG CCC AGA GTC 
TCC 
E72A_For Qucik-change-mutagenesis-
primer sense E72A mutation 
5´ CTT CCT GGA ATT CCT GGA AAA GCA 
GGA AAA GCA GGA CCA ACT GGA CCC 
AAA GGA 
E72A_Rev Qucik-change-mutagenesis-
primer Antisense E72A 
mutation 
5´ TCC TTT GGG TCC AGT TGG TCC TGC 
TTT TCC AGG AAT TCC AGG AAG 
 
2.1.10. Equipment 
Apparatus  Manufacturer Apparatus  Manufacturer 
Agarose electrophoresis 
gel chamber  
Stratagene  Neubauer 
counting 
chamber 
Brand 
Autoclave  Webeco  Nitrocellulose 
transfer, 
0.45μM 
Whatman 
Blotting chamber  Hoefer  Petri dishes Hartenstein 
Blotting papers Grade 3 
MM Chr 
Whatman Pipettes  Eppendorf, Abimed  
Centrifuges Eppendorf, 
Sorvall, Heraeus 
Photometer Hitachi 
Computer Dell Precision 
balance  
Sartorius  
Counting chamber  Neubauer 
(improved)  
Shaker Bellco 
Biotechonology 
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Coulmns - Mini NEB Dialysis 
Cassettes 
Thermo-Scientific 
Digital chemical balance  Sartorius  Sterile bench  Heraeus  
Freezer  Liebherr, Nunc  Thermocycler  Eppendorf, Perkin 
Elmer  
Ice maker  Scotsman  UV 
crosslinker  
Stratagene  
Incubator  Heraeus, 
Memmert  
X-ray film Fujifilm 
 
2.1.11. Software and databases 
Product name Supplier 
Adobe Photoshop CS Adobe Systems Inc. USA 
Gene runner Hastings software 
Gel filtration analysis Unicorn evaluation software 
Literature 
http://www.ncbi.nlm.nih.gov/pubm
ed/ 
Microsoft Office Microsoft, USA 
Sequence analysis http://www.uniprot.org/ 
Statistical analysis 
http://www.graphpad.com/prism/p
rism.htm 
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2.2. Methods 
2.2.1. Molecular Biological Methods  
2.2.1.1. Amplification of DNA by polymerase chain reaction  
2.2.1.1.1. PCR 
The polymerase chain reaction (PCR) is a technique for oligonucleotide primer directed 
enzymatic amplification of a specific DNA sequence of interest. The PCR product is obtained 
from the DNA template in vitro applying a heat-stable DNA polymerase. An automated 
thermal cycler puts the reaction through 30 or more cycles of denaturation of dsDNA, 
annealing of primers and polymerization. Denaturation separates the complementary strands 
and was carried out at 92 °C. Annealing temperature  was calculated based on the primer 
sequence (Tm). Primers are single-stranded oligonucleotides complementary to the flanking 
areas of the targeted segment which serve as a starting point for DNA replication. During 
polymerization the enzyme catalyzes the synthesis of a new strand DNA. The optimal 
temperature varies according to the polymerase species. PCR products were visualized on 
an agarose gel. 
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*1 min per 1000 bp of DNA sequence of interest was calculated for the duration of the 
elongation step based on the average processivity of the specific polymerase.  
Taq Pol → 1 min/kb DNA sequence  
Pfu Pol → 2 min/kb DNA sequence  
Pfx Pol → 1 min/kb DNA sequence, operates at 68°C  
The basic melting temperature Tm of the primers was calculated with the formula:  
Tm= 2 x (aA +bT) + 4 x (cG +dG) [ °C], where a, b, c, and d are the numbers of bases A, T, 
G and C in the primer sequence, respectively.  
Tmr= Tm – 5 (or 4) [ °C], without taking into consi deration the restriction endonuclease 
recognition site sequence (additional to the gene specific sequence)  
TmR= Tm – 5 (or 4) [ °C], calculating the entire pr imer, including the introduced 
endonuclease recognition site. 
2.2.1.1.2. Reverse transcription PCR (RT-PCR) 
The RT-PCR method is used to translate RNA to its DNA complement (complementary DNA, 
or cDNA) by using the enzyme reverse transcriptase. The cDNA is then amplified using a 
traditional PCR with a DNA polymerase. Three different types of primers could be used for 
the RT-step: random primers, oligo (dT) primers or gene specific primers. There are two 
ways to perform a RT-PCR, first the RT-step could be performed in the same reaction tube 
like the following PCR-step (one-step RT-PCR). On the other hand, the PCR-step could be 
performed in another reaction tube (two-step RT-PCR). 
In this work, the RT reaction was carried out with the Reverse Transcription Kit in a 20 µl final 
volume under the following conditions:                                 
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                    Final concentration 
MgCl2 5 mM 
dNTPs  1 mM each  
Oligo (dT)15 primer 0.5 µg  
RT Buffer  1x  
AMV reverse transcriptase 15 U/µl  
RNasin  1 U/µl  
RNA template  1 µg  
The reaction was incubated at 42° for 15 minutes (f irst strand cDNA synthesis) followed by 5 
minutes duration at 95°C and cooling down to 4°C fo r 5 minutes. The first strand of cDNA 
synthesized during this step was used as the template for the coupled standard PCR 
reaction. 
2.2.1.1.3. Colony PCR  
Colony PCR is a rapid method for screening for positive bacteria clones on a plate 
subsequent to DNA cloning. Gene specific primers of the desired sequence were used for a 
Taq-PCR reaction mix. The reaction mix was aliquoted to 10 PCR tubes on ice. Single 
isolated bacteria colonies from a LB-plate were picked with an autoclaved toothpick into the 
PCR-tubes containing the mix. The tested colonies were transferred to a fresh LB-plate for 
further usage. Cell lysis was achieved by an additional initialization heating step at 95°C for 3 
min in the thermocycler (Eppendorf) prior to the standard PCR-program. PCR-products were 
analyzed by agarose gel electrophoresis. Cultures for positives clones were prepared for 
plasmid DNA isolation.  
2.2.1.2. DNA Cloning  
DNA cloning is a technique for DNA fragments reproduction. A vector is required to carry the 
DNA fragment of interest into a host cell. All cloning vectors used in the course of this work 
were plasmids. Plasmids are small circular molecules of double stranded DNA derived from 
natural plasmids that occur in bacterial cells. A DNA fragment can be inserted into a plasmid 
if both, the circular plasmid and the source of DNA, have recognition sites for the same 
restriction endonuclease. The plasmid and the foreign DNA are cut by a restriction 
endonuclease producing intermediates with sticky and complementary ends. After ligation 
the new plasmid can be introduced into bacterial cells and produce many copies of the 
inserted DNA.  
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2.2.1.2.1. Generating a DNA insert  
DNA inserts were generated by PCR and products were separated on an agarose gel and 
purified. Subsequential incubation with restriction endonucleases produced blunt ends or 
single-stranded overhangs (cohesive ends also called sticky ends) complementary to those 
in the vector. Primers were designed to provide a restriction site at each end of the PCR 
product. In other cases the PCR products contained the cleavage site. Accurate digestion 
was verified by agarose gel electrophoresis, followed by purification of the digested products. 
 
The temperature of incubation, the choice of reaction buffer as well as the amount of units 
applied were dependent on the restriction endonuclease’s requirements. Duration of 
incubation was in most cases minimum 2 h. In case double digestion was not suitable, the 
cDNA was subjected to cleavage by one enzyme at a time, followed by gel electrophoresis 
and extraction. 
2.2.1.2.2. Generating recombinant plasmid DNA  
Plasmid DNA was cleaved by corresponding restriction endonucleases which produced 
cohesive ends complementary to the insert DNA. After verification of a successful plasmid 
linearization and vector fragment integrity by gel electrophoresis, the vector was purified 
using the Promega Gel Extract Kit according to manufacturer’s instructions. 
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The temperature of incubation and the choice of reaction buffer, as well as the amount of 
units applied were dependent on the restriction endonuclease’s requirements. Duration of the 
incubation was 0.5-1 h. In case a double digestion was not suitable DNA was subjected to 
cleavage by one enzyme at a time, followed by a gel electrophoresis and extraction. 
2.2.1.2.3. Noncohesive ends cloning  
If not having compatible restriction sites for a cloning procedure at hand, a blunt 
(noncohesive end) cloning was performed. Also, provided a restriction endonuclease 
generated noncohesive ends upon restriction of an insert, a blunt end cloning was carried 
out. The insert and vector terminii were both blunted by using E. coli DNA polymerase I large 
fragment (Klenow fragment, Roche) according to the manufacturer’s instructions. Klenow has 
5’-3’ polymerase and 3’-5’ exonuclease, but not 5’-3’ exonuclease activities. Next, the vector 
was dephosphorylated by using the calf intestinal phosphatase (CIP) to decrease the 
background of non-recombinants that arise from self-ligation. CIP was also employed 
according to the manufacturer’s instructions. Gel purification of the vector was performed to 
reduce the frequency of aberrant clones and were recovered from the gel by using the 
NucleoTrap gel extraction kit (Pro Omega). 
2.2.1.2.4. Site-directed Mutagenesis  
Specific deletions were introduced into cloned DNA using completely overlapping sense and 
antisense primers containing the mutation of interest. Mutagenic primers lacking the DNA 
sequences designated for deletion were employed for PCR amplification using cDNA for full-
length wild-type ficolin-B as template and the Pfx DNA Polymerase (Invitrogen), according to 
the manufacturer’s conditions. Primers were extended for 10 min at 68°C during which the 
desired mutations were incorporated and subsequently amplified. The PCR products 
obtained were two different linear DNA fragments, the parental template and the mutated 
DNA. Parental template DNA was subjected to degradation by DpnI digestion (30 U/50 µl 
PCR sample, for 1 h at 37°C). Subsequently, DpnI en donuclease was heat inactivated for 15 
min at 65°C. Mutant DNA was circularized by blunt e nd ligation, achieved by transforming 
competent E. coli DH5α bacterial cells with DpnI-treated PCR sample. The sequences of  
mutant was confirmed by double-stranded DNA sequencing (Geneart, Regensburg). 
2.2.1.2.5. Ligation  
Ligation is the process of joining linear DNA fragments together with a covalent bond. A 
phosphodiester bond between the 3’-hydroxyl termini and the 5’-phosphate is catalyzed by 
the T4 DNA ligase. The enzyme originates from the T4 bacteriophage and ligates DNA 
fragments having blunt and sticky ends annealed together. The optimal incubation 
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temperature for T4 DNA ligase is 16°C. Following ge neration and purification of insert and 
vector DNA fragments, the fragments were eluted together in 1x T4 ligase buffer and 
supplemented with T4 DNA ligase (NEB). To maximize the yield, a ligation reaction was set 
in an estimated vector:insert molar ratio of 3:1. Following over night incubation at 16°C or 
2hours at room temperature, the total reaction was used for transformation of competent 
cells. 
 
2.2.1.2.6. Transformation and culturing of E.coli DH5α bacterial cells  
Transformation is the process of uptake of exogenous plasmid DNA into a bacterium. 
Bacteria that are capable of being transformed are called competent. Competent cells are 
prepared by treatment with rubidium chloride (RbCl). Cells are treated with a hypotonic 
solution containing RbCl. It increases the ability of a prokaryotic cell to incorporate plasmid 
DNA allowing them to be genetically transformed. The addition of rubidium chloride to a cell 
suspension promotes the binding of plasmid DNA to the cell surface, which can then pass 
into the cell. Transformation of bacterial cells is achieved by an uptake of plasmid DNA. The 
procedure involves heat shocking and ice shocking alternately. 20 µl of a ligation reaction 
were added to 200 µl competent bacterial cells (E. coli DH5α) previously thawed on ice, 
gently mixed and incubated on ice for further 40 min. Cells were heat shocked for 90 s at 
42°C and chilled on ice for 2 min. 1 ml LB was adde d and the cells were incubated under 
shaking for 30-60 min at 37°C. Cells were collected  by centrifugation at 3500 rpm for 3 min at 
RT. Supernatant was discarded and the cell pellet was dissolved in 150 µl LB. Next, 50 µl 
and 100 µl were plated out on LB agar plates containing the appropriate antibiotic as 
selection marker and plates were incubated overnight at 37°C. Colonies of transformants 
were inoculated for further investigation or plates were stored for several weeks at 4°C. For 
bacterial culture and subsequent plasmid purification, designated transformed E. coli DH5α 
clones were shaken over night in LB broth supplemented with either 100 µg/ml ampicillin or 
100 µg/ml kanamycin at 37°C. Later cells were pelleted a nd plasmid DNA was isolated 
employing the Plasmid Maxi Kit (Qiagen) according to manufacturer’s protocol. 
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2.2.1.3. Separation of nucleic acids by Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used to separate DNA fragments based on their 
size. DNA is negatively charged in solution and is forced to migrate through an agarose gel 
to the positive pole by an electric field. Migration rate is inversely proportional to the 
logarithm of the number of base pairs. Longer molecules move more slowly due to their 
entrapment in the gel matrix. Gel agarose concentration is chosen to be appropriate for the 
size of DNA fragments. Concentration of 0.7%-agarose gels shows good resolution of large 
DNA molecules (up to 12 kb), whereas 2%-agarose gels are suitable for smaller molecules 
(down to 0.2 kb). DNA can be visualized by illumination by UV light (Bachofer GmBH) based 
on the incorporation of fluorescent dye (ethidium bromide) into the DNA helix. If the DNA was 
to be used for further cloning procedures only brief exposure to UV light was performed to 
minimize the risk of DNA damage. The agarose (% (w/v) = gel concentration) was dissolved 
by boiling in 0.5x TBE buffer (microwave). After cooling to 60°C ethidium bromide was added 
to a final concentration of 5 µg/ml. DNA-loading buffer was added to the DNA samples. Gels 
were run usually at 100 volts for 30-60 min. The agarose gel areas containing the DNA 
fragments of interest were excised and DNA was recovered from the gel by employing 
Quiagen or Promega Gel Extraction Kit according to manufacturer’s protocol. 
 
2.2.1.4. Isolation of nucleic acids from aqueous solutions  
2.2.1.4.1. Alcohol precipitation  
Ethanol precipitation is a rapid technique to concentrate DNA. A DNA precipitate is allowed 
to form in ethanol in the presence of moderate concentration of monovalent cations (0.1 
volumes of 3M Sodium acetate). Initial precipitation was done with 2 to 2.5 volumes of ice 
cold absolute ethanol for 20 min at low temperature (-20°C). DNA was recovered by 
centrifugation at 15000 g for 20 min at RT. Next, the precipitate was redissolved in ice cold 
70% ethanol, followed by a brief centrifugation eliminating the residual salt. After drying the 
pellet was resuspended in an appropriate buffer or MPH2O. Isopropanol can be used instead 
of ethanol. One volume isopropanol was added to the aqueous solution. Precipitation was 
achieved by mixing and incubation for 10 min at RT. DNA precipitate was collected by 
centrifugation at 15000 g for 10 min at RT. Isopropanol and salt were removed by 
subsequent wash with ice cold 70% ethanol.  
Isolation of plasmid DNA from bacterial cells was carried out by using Qiagen Plasmid Maxi 
Kit and Qiagen Plasmid Giga Kit following the manufacturer’s instructions. 
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2.2.1.5. Isolation and purification of plasmid DNA 
2.2.1.5.1. Mini-scale isolation of plasmid DNA (“Minipreps”) 
Mini-scale isolation of plasmid DNA was performed using the Wizard Plus SV Minipreps DNA 
Purification System (Promega). This kit combines two techniques: alkaline lysis and silica 
resin-based DNA purification. Cells are partially lysed using an alkaline solution of the 
detergent SDS.  This allows small plasmid DNA molecules to escape from the cell, while 
genomic DNA remains within the cells.  When a concentrated potassium acetate solution is 
added to the cell lysate, cell debris (containing high molecular weight genomic DNA) is 
precipitated, while plasmids and soluble proteins remain in solution.  If cell membranes are 
dissolved completely, sheared genomic DNA may be released, contaminating the plasmid 
preparation.  To avoid this, the lysis step is carried out for a limited time – just enough for the 
solution to clear. The adhesion of DNA to a silica matrix is based on the observation that 
nucleic acids adhere to silica in high-salt conditions, but not in low-salt conditions. DNA will 
bind to silica in the lysis solution, and will be eluted from the matrix by TE buffer (see section 
“Buffers”). 
Colonies were picked and cultured in LB medium containing 100 µg/ml ampicillin at 37°C 
overnight under vigorous shaking. The experimental procedure was carried out according to 
the manufacturer’s instructions. Briefly, 3 ml of overnight bacterial culture were centrifuged 
for 5 min and the pellet resuspended in 250 µl of Resuspension Solution. After lysis with one 
volume of Cell Lysis Solution the reaction was stopped by adding 350 µl of Neutralization 
Solution and pelleted at top speed for 10 min at RT. The clear lysate was then decanted into 
a Spin Column containing the silica-resin, and washed extensively before the DNA was 
eluted with 100 µl of TE buffer. Plasmid identity was checked by restriction digestion and the 
DNA stored at 4°C. 
 
2.2.1.5.2. Scaled-up preparation of plasmid DNA (“Maxipreps”) 
Maxiprep isolation of DNA was performed to obtain high yields of purified plasmid DNA for 
further transformations and transfections. Positive clones were chosen and plasmids were 
isolated using the Plasmid Maxi Kit (QIAGEN). This protocol is based on a modified alkaline 
lysis procedure, followed by binding of plasmid DNA to an anion-exchange resin under 
appropriate low-salt and pH conditions. While RNA, proteins, dyes and low-molecular-weight 
impurities are removed by a medium-salt wash, plasmid DNA is eluted in a high-salt buffer 
and then concentrated and desalted by isopropanol precipitation. 
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Briefly, 200 ml LB medium containing 100 µg/ml ampicillin was inoculated with the starter 
culture in a 1/1000 ratio, and incubated overnight at 37°C under vigorous shaking. After 
spinning down at 6500xg for 15 minutes, cells were resuspended extensively in Buffer P1 
containing RNase A, sequentially lysed in Buffer P2 for 5 min and neutralized in chilled Buffer 
P3. The lysate was then centrifuged (20,000xg, 30 min) to pellet the cell debris and the clear 
supernatant was decanted into a QIAGEN-tip 500 containing the anion-exchange resin. The 
resin was washed with medium-salt- and DNA eluted with high-salt-containing buffers. DNA 
precipitation was performed by adding 0,7 volumes of isopropanol and further centrifugation 
(14,500xg for 30 min). Before resuspending the DNA in water, the pellet was washed with 
70% ethanol. All centrifugation steps were carried out at 4°C. Plasmid identity was checked 
by restriction digestion and the DNA stored at 4°C.  
 
2.2.1.6. Isolation of total RNA  
To investigate the expression pattern of ficolin B in mouse tissue, total RNA was isolated 
from different organs using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s 
instructions. Briefly, after excision samples (up to 30 mg, depending on the organ) were 
immediately placed in RNAlater solution which permeates the tissue to stabilize and protect 
cellular RNA in situ. Stabilized tissue samples were then disrupted in buffer containing highly 
denaturing guanidine isothiocyanate (to inactivate RNases) by a rotor-stator homogenizer 
(Ultra-Turrax T25, Ika® Labortechnik), which causes disruption by a combination of 
turbulence and mechanical shearing. Disrupted tissue was then homogenized to reduce 
viscosity of the cell lysate by shearing the high-molecular-weight genomic DNA and cellular 
components to create a homogeneous lysate. Homogenization was performed using the 
QIAshredder Kit (QIAGEN). Ethanol was then added to provide appropriate binding 
conditions and the lysate applied to a column where the total RNA binds to the membrane 
and contaminants are washed away. Eventually, on-column DNase digestion was carried out 
with the RNase-Free DNase Set (QIAGEN) and high-quality RNA was finally eluted with 
DEPC-water. 
 
2.2.1.7. Gel DNA recovery  
Following gel electrophoresis analysis DNA fragments of interest were excised and 
recovered from the gel by using the Promega Gel Extract Kit following the manufacturer’s 
instructions.  
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2.2.1.8. Quantification of nucleic acids by spectrophotometry  
ssDNA, dsDNA and RNA absorb light in ultraviolet range, most strongly in 254-260 nm 
range. The measurement at 260 nm GeneQuantII photometer (Pharmacia Biotech) allows a 
calculation of the dsDNA concentration. An OD260 of 1 corresponds to approximately 50 
µg/ml of dsDNA. The ratio between measurements at 260 nm and 280 nm provides an 
estimate of the purity of the samples. Proteins absorb light at 280 nm.  
Formulas:  
C (double stranded DNA) = OD260 x factor of dilution x 50 [µg/ml]  
C (RNA and oligos) = OD260 x factor of dilution x 40 [µg/ml]  
1 µl DNA (or RNA) sample was dissolved in MPH2O (1:100) and photometrically examined 
(Hitachi). Nucleic acid concentration was calculated employing the formulas (Lambert-Beer’s 
law) described above.  
2.2.1.9. Sequencing  
The integrity of plasmid constructs was checked by sequencing before proceeding to further 
applications. DNA plasmids were sequenced by Geneart, Regensburg. The obtained 
sequence data were compared with the published sequence in the database (PubMed, 
Swisprot, uniprot). Clones without any mutations were used for further work. 
 
2.2.2. Protein biochemical Methods  
2.2.2.1. Electrophoretic separation of proteins (SDS-PAGE) 
Polyacrylamide gel electrophoresis (PAGE) is applied to separate protein mixtures based on 
their migration in solution in response to an electric field. The sample is run in a support 
matrix which separates the molecules by size and provides a record of the electrophoretic 
run. Proteins are amphoteric compounds, therefore their net charge is determined by the pH 
of the solution. The net charge is independent of its size, i.e. the charge is carried per unit 
mass. Under denaturing conditions the anionic detergent sodium dodecyl sulfate (SDS) 
disrupts the secondary and tertiary structure and binds to proteins quite specifically in a mass 
ratio of 1.4:1. Therefore SDS confers a negative charge to the polypeptides in proportion to 
their length (equal charge per unit length). 2-mercaptoethanol reduces disulphide bridges in 
proteins. During denaturing SDS-PAGE separation is achieved by polypeptide migration 
determined not by its intrinsic electrical charge, but by its molecular weight.  
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Throughout the course of this work, protein samples were subjected to SDS-PAGE using a 
discontinuous buffer system providing a good resolution. In a discontinuous system a non-
restrictive large pore gel, called stacking gel, is layered on top of a separating gel, called a 
resolving gel. Each gel was made with a different buffer along with the tank buffer being 
different from the gel buffers. Prior to loading, protein samples were added 1x SDS-loading 
buffer and boiled for 5 min at 100°C. Protein sizes  were analyzed using the pre-stained 
Protein Ladder (Fermentas, Bio-Rad) as molecular mass marker. Electrophoresis was 
performed at 36 mA at RT until the BPB (bromphenol blue) dye reached the bottom of the 
gel. 
2.2.2.2. Electroblotting and immunodetection  
Proteins were transferred efficiently from a polyacrylamide gel to a PVDF membrane by 
electroblotting (Western blot) using a Biorad blotting tank. The transfer was carried out for 
1.5 to 2 h at 150 mA at RT in western transfer buffer. Protein transfer was verified by staining 
the nitrocellulose membrane with Ponceau S solution (Sigma). For immunodetection the 
PVDF membrane was blocked over night in blocking buffer at 4°C. After blocking the 
membrane was incubated in blocking buffer containing the corresponding primary antibody 
for 3 h at RT. Subsequently, the membrane was washed 3 times with PBST for 10 min at RT 
with shaking. Next, the membrane was incubated in PBST: blocking buffer 3:1 (v/v) 
containing the secondary HRP-linked antibody for 45 min at RT followed by a second 
washing as described above. Finally, the exceed liquid was removed and the antibody 
coupled peroxidase was detected with an ECL reagent kit (enhanced chemoluminescence, 
Amersham). Signals were detected by autoradiography using an ECL-hyperfilm (Amersham). 
2.2.2.3. Ponceau S staining  
To  control  the  efficient  transfer  of  the  proteins  to  the  PVDF  membrane,  the 
membrane  was  incubated  in  Ponceau  solution  for  1  min  and  briefly  washed  with 
TBST-buffer.  The  positions  of  the  standard  marker  proteins  were  labeled  with  a pencil.  
Afterwards,  the  membrane  was  destained  in  TBST  buffer  for  several  times until  the  
red  color  was  completely  removed.  For  the  preparation  of  the  staining solution 2 g 
Ponceau S (Sigma-Aldrich) was dissolved in 100 ml 3 % trichchloracetic acid.   
2.2.2.4. Dot blot 
Dot blots were performed either to assess the ability of poly- and monoclonal antibodies in 
detecting non-reduced ficolin-B or to evaluate the binding affinity of ficolin-B to different 
organic compounds. In each case ficolin-B (in different concentrations) or the supernatant (1 
to 5µl) were spotted on a nitrocellulose membrane at the corresponding concentration and let 
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air-dry for 30 minutes before blocking with 1% low fat dry milk powder in TBS/0,05%Tween. 
The following detection steps were identical to a Western Blot. 
2.2.2.5. Western Blot stripping 
Membrane stripping is the removal of antibodies (including primary and secondary) from a 
western blot membrane, to allow the further incubation of the membrane with other primary 
and secondary antibodies. The membrane was incubated with prewarmed 50 ml Stripping 
buffer (-mercaptoethanol was freshly added) at 60 °C for 15 minutes. That incubation step 
was repeated 3 times. After the third incubation, the membrane was washed with PBST four 
times for 10 minutes at room temperature. 
 
2.2.2.6. BCA assay 
Protein concentrations were determined using the Pierce Endogen BCA (Thermo Scientific 
Inc., Rockford, USA) assay according to the manufacturer’s protocol (microplate procedure). 
Preparation of the BCA™ working reagent:  
Prepare working reagent by mixing 50 parts of BCA™ Reagent A with 1 part of BCA™ 
Reagent B. (e.g. 5 mL of Reagent A with 100 µL of Reagent B) 
Microplate procedure protocol: 
1. Pipette 10 µL of each standard or unknown sample replicate into a microplate well 
(working range = 20 – 2000 µg/mL). 
2. Add 200 µL of the working reagent to each well and mix the plate thoroughly on a 
plate shaker for 30 seconds. 
3. Cover Plate and incubate at 37°C for 30 minutes.  Cool plate at RT. 
4. Measure the absorbance at 562 nm. 
2.2.2.7. Bradford assay  
Normalization of total protein amounts was performed using Bio-rad Bradford reagent. 5µl of 
protein lysates was added to 795 µl of milli Q water. 200µl of reagent was added and reading 
was taken after 5 min at λ595 using a Bio-Rad spectrophotometer 3000. 
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2.2.2.8. ELISA 
Enzyme-linked immunosorbent assay (ELISA), is a biochemical technique used mainly in 
immunology to detect the presence of an antibody or an antigen in a sample. Nunc Maxisorb 
plates were coated with AcBSA (10µg/ml), BSA (10µg/ml), or 100ul of chitin beads (NEB) in 
coating buffer (5mM Ca2+/TBST) for overnight at 4°C in 100 µl/well volume.  Blocking of 
unspecific sites was performed with 5% milk powder in TBS (200ul) for 2 hours at RT and 
were subsequently washed thrice in TBST. In order to evaluate whether the binding was Ca2+ 
dependent, two buffer conditions were used. Ficolin-B is added to the plates in increasing 
concentrations (0.6, 1.25, 2.5, 5 µg/ml) and in different buffers (5mM Ca2+/TBST (or) 50mM 
EDTA/TBST) as indicated and kept for overnight at 4°C. The same blocking buffer was used 
to dilute the reagents of the following steps. Primary antibody (IA4- anti ficolin-B monoclonal 
antibody) was added and incubated at RT shaking for 2 hours. After washing, HRP or Pox 
conjugated  goat anti-rat antibody was used in a 1:3000 dilution for 2 hours at RT. Plates are 
washed and developed for 10-15min with OPD substrate containing H2O2. Addition of 50 
µl/well sulphuric acid terminated the enzymatic reaction. The absorbance at 450 nm was 
measured using a microplate biokinetics reader.  
 
2.2.2.9. Recombinant protein expression in prokaryotes  
The optimization of protein is carried out with various factors like temperature, IPTG 
concentration and time of induction. Induction of protein expression at 12–15°C can often 
help the folding and the solubility of the fusion protein and increase the cleavage efficiency. 
The optimal incubation temperature and time for induction will vary depending on the target 
protein. 
Briefly, E. coli strain BL21DE3pLys was transformed with the recombinant protein expression 
vector pTXB1, coding for C-terminally Intein-fused proteins. The bacterial culture was grown 
in LB broth supplemented with 100 g/ml ampicillin and 34 g/ml chloramphenicol. The  
BL21DE3pLys strain contains a pRARE plasmid (camr) coding for tRNAs of the rarely used 
codons Arg, Ile, Gly, Leu and Pro, enabling high protein expression yields (Novy et al., 
2001). The recombinant protein transcription driven by a lacZ promotor was then induced 
with isopropyl-β-D-thiogalactopyranoside (IPTG). Initially, the recombinant host was grown 
over night to saturation in LB with shaking (180 rpm) at 37°C. Next, 1 litre of LB broth were 
inoculated with the primary culture (10:1) and incubated with shaking (180 rpm) at 37°C to 
A600 of 0.6. Recombinant expression was then induced by 1 mM IPTG (to 0.1 mM) and cells 
were cultured for 4 hours with shaking (180 rpm) at 30°C. Finally, cells were pelleted 
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(Beckmann GSA, 10000 g, 10 min, 4°C), subsequently washed onc e with PBS and if 
required stored at -20°C.   
To optimize expression, varying induction temperature and time was tested at (37°C for 2–4 
hours, 30°C for 4–6 hours, 22–25°C for 6–16 hours a nd 12–15°C overnight using 0.4 mM 
IPTG). One sample with no IPTG should be incubated as a control for uninduced cells. 
Varying IPTG concentrations (up to 1 mM) can also be tested. Lowering the IPTG 
concentration (0.01–0.1 mM) may also reduce the fusion protein expression in inclusion 
bodies. For low temperature induction (e.g.12–15°C)  the culture can be incubated at 37°C 
until the OD600 reaches 0.6–0.7 and further induction carried at low temperature. Fusion 
protein expression can be examined by SDS-PAGE, followed by Coomassie staining or 
western blot analysis. If the fusion protein is not detected by Coomassie staining, a Western 
blot with the anti-Chitin Binding Domain Serum may be performed as the intein fusion protein 
contains a Chitin binding domain (CBD) site. 
 A frozen stock of E.coli BL21 (DE3) pLysS carrying the desired vector was used for 
inoculation of 5 mL of LB medium supplemented with the respective selective antibiotic. Cells 
were grown at 37°C in a shaking incubator at 180 rp m for 14 to 16 hours. 2 mL of this culture 
were used for inoculation of 100 mL of fresh LB medium containing the selective antibiotic 
and this culture was then grown at 30°C to an OD 600 of 0.6 to 0.8. Before induction of protein 
expression, a 2 mL aliquot of the suspension was collected and centrifuged at 14000x g for 2 
minutes in a tabletop centrifuge. The supernatant was discarded and the pellet was 
resuspended in 100 µL of 1x protein sample buffer and stored on ice at -20°C for overnight. 
Protein expression was induced by the addition of IPTG (final concentration of 0.1 mM) and 
the incubation temperature was reduced to 20°C (ano ther sample at 30°C). Thereafter, 
several samples (2 mL) were taken at indicated timepoints and centrifuged for 2 minutes at 
14000x g a tabletop centrifuge. Supernatants were discarded and pellets were stored on ice 
at -20°C for overnight. 
The 2 mL overnight stored pellets were lysed with cell resuspension buffer pH 7,6 and further 
treated with PMSF, DTE and ß-Mercaptoethanol. The samples are vortexed and placed in 
ice for 15 minutes. This was again resuspended in Lysozyme, Sodium deoxycholate, 
Magnesium chloride and DNaseI with each time repeated vortexing and placement of the 
sample on ice for 15 minutes. Finally the lysed and resuspended sample was centrifuged at 
4°C, 14000rpm for 30 minutes to get it separated in to pellet and supernatant. 
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2.2.3. Chromatography Methods 
2.2.3.1. Intein based affinity chromatography 
The Ficolin-B was overexpressed and purified by using the intein–CBDsystem according to 
the basic protocol provided by New England Biolabs. pTXB1 (NEB) contains a mini-intein 
from the Mycobacterium xenopi gyrA gene (Mxe GyrA intein; 198 amino acid residues) is 
used as tag for proteins for expression and purification applications. The target protein is 
fused at its C-terminus to a self-cleavable intein tag (~28 kDa) that contains the chitin binding 
domain (CBD, 6 kDa) allowing for affinity purification of the fusion precursor on a chitin 
column.   
2.2.3.1.1. Protein purification from the soluble fraction 
For purification, the cells from 1 liter culture after a 4 hours incubation at 30°C in the 
presence of 1 mM IPTG were harvested. The pellet (about 8 g wet wt cells) was 
resuspended in 20ml of lysis bufferA (Section 2.1.2.1). All subsequent  steps were performed 
at 4°C. The cells were disrupted by sonication, and  the insoluble debris was removed by 
ultracentrifugation for 1 h at 16,000g. After lysis, cell debris was removed by 
ultracentrifugation for 1 h at 16,000g. The cleared lysate was applied directly onto a chitin 
column (New England Biolabs) preequilibrated with 10 vol of buffer A. After loading, the 
column was washed with 10 bed vol of buffer A. The column buffer was exchanged with 
cleavage buffer (Section 2.1.2.1) by quickly washing the column with 3 bed vol. The flow was 
then stopped and the column was left at 4°C for 20 h. The ficolin-B elution was carried out by 
continuing the column flow with buffer A. Chromatography eluted samples were concentrated 
by ultrafiltration using Amicon Ultra (Mwco: 10K) ultrafiltration-devices (Millipore).  The ficolin-
B content of the fraction was analyzed by SDS– PAGE, and protein concentrations were 
determined by using the Bradford dye binding assay (Bio-Rad Labora- tories) and bovine 
serum albumin as the standard.  
 
2.2.3.1.2. Protein purification from inclusion bodies 
Protein pellet was resuspended in cell lysis buffer (Section 2.1.2.1) and centrifuged at 
16,000g for 20 min at 10 °C. The cells were disrupted by s onication and spinned down cell 
debris containing the inclusion bodies at 16,000 g at 4°C for 30 minutes. The supernatant 
was discarded and the pellet was resuspend in 100 ml breaking Buffer (50 mM Tris–HCl, pH 
7.5, 200 mM NaCl and 7M Guanidine-HCL). The solution was stirred for 1 hour at  4°C and  
remaining cell debris were spin down at 16,000 g and 4°C for 30 minutes. The  supernatant 
was loaded into dialysis bag and dialyzed against renaturation Buffer A, B, C, D and 2 times 
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E according to IMPACT kit manual. Each step is against 1 L of a renaturation buffer and 
should take at least 3 hours at 4°C. During dialysi s the buffer should be continuously stirred. 
Finally Centrifuge the dialyzed solution containing the renatured protein at 16,000 g and 4°C 
for 30 minutes to remove any remaining impurities or incorrectly folded protein which is again 
aggregated. After sample centrifugation, the standard protocol for chitin chromatography 
(New England Biolabs, Beverly, MA, USA) and cleavage reaction was used to elute the 
protein product and further analyzed both the eluate and chitin beads for cleavage efficiency 
and protein solubility. 
Chromatography eluted samples were concentrated by ultrafiltration using Amicon Ultra 
(Mwco: 10K) ultrafiltration-devices (Millipore). Stripping of intein-CBD from chitin column was 
carried out using 20 mM Tris–HCl buffer, pH 8, containing 500 mM NaCl and 1% SDS 
solution. 
 
2.2.3.2. Gel filtration 
Gel  filtration  analysis  is  a  method  used  for  the  analysis  of  the  apparent  size  of  
proteins  or  protein  complexes  under  native  conditions.  For  purified recombinant 
proteins, gel filtration provides evidence about the formation of di-,  tri,  or  oligomers  if  the  
elution  of  the  protein  of  interest  is  compared  to  that  of marker molecules of known 
molecular mass.   
Molecular weight determinations by gel filtration are carried out by comparing average elution 
volume parameter, such as Kav of the protein of interest, with values obtained for several 
known calibration standards. A calibration curve was prepared by measuring the elution 
volumes of several standard proteins, calculating their corresponding Kav values and plotting 
their Kav values versus the logarithm of their molecular weight. The apparent molecular 
weight of an unknown protein can be determined from the calibration curve once its Kav 
value is calculated from the measured elution volume. The Kav was calculated using the 
formulae given below. 
 
The calibration curve was plotted from the calculated Kav to logarithm of the molecular mass 
for the various standards (Fig.1). To calculate the molecular mass of the unknown protein 
from Kav a formulae was deduced from the calibration curve using the computer program. 
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                     Fig. 2.1 Plot of the Elution volume Ve/Vo  versus log MW in gel filtration. 
Gel filtration chromatography was conducted on a computer-controlled ÄKTATM purifier high 
performance liquid chromatography equipped with  Superdex 200 column (10 mm x 30 cm; 
GE Healthcare) equilibrated in 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl at a flow 
rate of 0.5 ml/min, at room temperature.  The injection volume of the proteins was 100µl with 
concentrations ranging from 0.226mg/ml for the “Old ficolin-B” and 0.408mg/ml for the “fresh 
ficolin-B”.  Eluted proteins were collected in 1 mL fractions and analysed by Western blot to 
verify the identity of the proteins in the distinct peak fractions.  
Molecular weight calibration of the analytical gel filtration column was done using the 
Sigma gel filtration molecular mass standard kit 12,000–200,000 Da (cytochrome c, 12.4 
kDa; carbonic anhydrase, 29 kDa; bovine serum albumin, 66 kDa; alcohol 
dehydrogenase, 150 kDa; b-amylase, 200 kDa). Data analysis and processing were done 
with the Unicorn evaluation software (GE Healthcare) and Sigma Plot 9.0 (Systat 
Software®). Values in brackets are the Stoke’s radii of protein standards. The Stoke’s 
radii of ficolin-A oligomers were determined from a graph of [–log(Kav)]1/2 against the 
Stokes radius of protein standards, where Kav is the partition coefficient, Ve is the elution 
volume of the protein, and V0 and Vt are the void and total volumes of the gel filtration 
column, respectively. 
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2.2.4. Cell Biological Methods 
2.2.4.1. Cell culture techniques- Drosophila Schneider-2 (S2) cells  
Transfection of S2 cells 
S2 cells were stably transfected with the “pMT-pCoHygro-ficolin-B” (fusion vector) wild type 
and mutant constructs in order to express the ficolin -B proteins, respectively. The fusion 
vector allows us for single transfection and leads to have more positive clones. 
Stable transfection is optimal for long-term storage, high protein expression, and large-scale 
production of the desired protein. In addition, the Drosophila Expression System (DES®, 
Invitrogen) offers a convenient non-lytic system that uses simple plasmids for stable 
expression of heterologous proteins in S2 cells. Protein expression using the DES occurs in 
healthy, logarithmically growing cells, so high yields of high-quality protein can be produced 
(Johansen et al. 1989), (Deml et al. 1999). Drosophila melanogaster transfected cell lines 
generally contain multicopy inserts of the foreign gene that form arrays of more than 500-
1000 copies in a head to tail fashion. 
In order to generate a stable recombinant cell line, the plasmid (pMT-pCoHygro) containing 
the sequence of interest was transfected. The plasmid has a resistance-bearing pCoHygro 
vector that constitutively expresses the hygromycin resistance gene (HPH) (Gritz and Davies 
1983) for selection of transfectants with the antibiotic hygromycin B. When added to cultured 
S2 cells, hygromycin B acts as an aminocyclitol to inhibit protein synthesis by disrupting 
translocation and promoting mistranslation. 
In this work, transfection was performed with the DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl-sulfate). DOTAP is a liposomal transfection reagent for the 
delivery of negatively charged biomolecules such as DNA, RNA, oligonucleotides, and 
protein into eukaryotic cells. It can be used for the highly efficient transfection of DNA into 
eukaryotic cells for transient or stable gene expression. Due to these features, it assembles 
DNA into compact structures, thus optimizing its entry into the cell. DOTAP-DNA complexes 
possess a net positive charge, which allows them to bind to negatively charged receptors 
(e.g. sialylated glycoproteins) on the surface of eukaryotic cells. Once inside, the reagent 
buffers the lysosome after it has fused with the endosomes, leading to pH inhibition of 
lysosomal nucleases and stability of DOTAP-DNA complexes. 
Cells were seeded onto a 6cm plate 24 hrs prior to transfection such that they were 50-70% 
confluent on the day of transfection. For each transfection in a 6cm plate, 2µg of total 
plasmid DNA was suspended in HBS and was added to 14µl of DOTAP (Roche) and DNA-
liposomal complexes were allowed to form by incubating for 10 min. Meanwhile, the medium 
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from the plates was replaced with DMEM without FBS. DNA-Liposomal complexes formed 
were added to the cells and incubated at standard growth conditions. The medium was 
replaced with normal growth medium containing FBS 4 hrs later. Cells were cultivated for 3 
days under normal conditions and then the selection reagent was incorporated to the normal 
growing medium (300 µg hygromycin B per ml of medium) which was replaced every 4-6 
days. Selection took place over 4 weeks and was monitored by comparison to the control 
flask containing cells transfected in the absence of the pCoHygro vector. Cells transfected 
with the empty pMT-pCoHygro vector served as a negative control. 
 
2.2.4.2. Induction of protein expression 
Stable transfectants were induced to express the protein by the addition of 500 µM CuSO4 
(final concentration) to the culture medium. To check for protein expression, supernatant 
aliquots were taken 2-3 days after induction and analysed by Western Blot. For high yield 
production of the recombinant protein supernatant was collected 10 days after induction and 
subjected to metal-affinity chromatography. 
 
2.2.4.3. Protein purification 
Ten days after induction, the conditioned medium was collected and cleared by 
centrifugation at 3000xg for 10 minutes at 4°C. Binding to the resin was per formed batchwise 
(1 ml resin/L medium, enough to bind approximately 5 mg His-tagged protein) overnight at 
4°C under rotation. The resin-Cu 2+-protein slurry was then poured into a column and 
attached to the BioRad Econo System device (BioRad) to facilitate the forthcoming steps. 
Washing was performed sequentially at a rate of 0.5 ml/min with PBS until baseline UV 
absorbance monitored at 280 nm and then again with 10 mM imidazole in 0.5 M/PBS to 
remove non-specifically bound proteins. Competitive elution of the desired protein was 
carried out with 250 mM imidazole in 50 mM Tris pH 8.0. Elution fractions were collected in 
0.5 ml aliquots and analysed by SDS-PAGE (see section II.2.4.2). Finally, the column was 
stripped with 20 mM EDTA in PBS to remove any metal bound to the resin and re-
equilibrated with 50 vol of deionized water. 
Positive elution fractions were pooled, dialysed overnight against PBS at 4°C and stored in 
aliquots at -20°C. Freezing/thawing cycles were alw ays avoided. Protein concentration of the 
samples was assessed by BCA assay (see section 2.2.2.6) 
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3. Results 
The use of bacteria in order to produce recombinant protein has grown in the recent years. 
Using recombinant DNA and inserting it into a plasmid of rapidly reproducing bacteria 
enables the manufacture of recombinant protein. These recombinant proteins can be a 
variety of different types, such as antibodies, antigens, hormones, and enzymes.  
Therefore, the first aim of this work was the synthesis of tag-free recombinant mouse ficolin –
B in an prokaryotic expression system, the genes of which have been sequenced (Fujimori et 
al., 1998;Ohashi and Erickson, 1998) and scanned in search of conserved domains and 
potential posttranslational modification sites. However, very little is known about the 
properties of the proteins they encode. The whole process towards the generation of the 
recombinant ficolin-B consisted of (i) the cloning of the ficolin genes into an prokaryotic 
expression vector for (ii) protein production in prokaryotes and (iii) further purification by 
affinity chromatography. 
3.1. Cloning, expression, and purification of the intein-ficolin-B fusion protein 
In this work, mouse ficolin-B was expressed and purified from E. coli cultures taking 
advantage of the intein-mediated approach. The ficolin- B cDNA contains a 942-base pair 
(bp) open reading frame (ORF) encoding 314 amino acids. Figure 3.1 and 3.2 show the full 
length cDNA of ficolin-B.  
The aim of the present work was to demonstrate that the fusion of ficolin-B to intein could 
lead to an efficient purification strategy in a single chromatographic step. For this purpose, 
ficolin-B was fused to the C-terminus of the intein gene in pTXB1 vector (Impact Kit), and the 
expression of intein-ficolin-B chimeric protein (Morassutti et al., 2005, Pezza et al., 2004)  
was induced in E. coli cultures. Ficolin-B cDNA was cloned to the C-terminus of intein into 
the pTXB1 vector.  
 
Fig 3.1. Domain architecture of Ficolin-B protein: All known ficolin proteins share a 
common structure with an N-terminal Cysteine rich region followed by Collagen-like domain 
and a small neck region in the center. The C-terminus comprises of a Fibrinogen-like domain 
which is responsible for carbohydrate recognition. 
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A) 
Ficolin-B protein full length
Collagen-like domain:
Fibrinogen-like domain:
Ficolin-B
Ficolin-BFicolin-
Ficolin-B
Ficolin-B
 
B) 
 
 
Fig. 3.2: Ficolin-B nucleotide and deduced amino acid sequences. A) Sequence 
alignment of ficolin-B mapping the collagen and fibrinogen domain. B) Ficolins are oligomers of 
structural subunits, each of which is composed of three identical 35-kDa polypeptides, 
respectively. Each subunit contains: an amino-terminal, cysteine-rich region; a collagen-like 
domain and a carboxy-terminal fibrinogen like-domain. (Fujita et al., 2002). 
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The IMPACT (Intein Mediated Purification with an Affinity Chitin-binding Tag) system 
is a novel protein purification system which utilizes the inducible self-cleavage activity of 
protein splicing elements (termed inteins) to separate the target protein from the affinity tag. 
It distinguishes itself from all other purification systems by its ability to purify, a native 
recombinant protein without the use of a protease in a single chromatographic step (Chong 
et al., 1997, Evans et al. 1998). Each intein tag contains a chitin binding domain (CBD) for 
the affinity purification of the fusion protein on a chitin resin. Induction of on-column 
cleavage, using thiol reagents such as dithiothreitol (DTT), releases the target protein from 
the intein tag (Figure 3.3).The vectors included in this kit allow for the fusion of the target 
protein at its C-terminus (pTXB1) or at its N-terminus (pTYB21) to the intein tag. The intein-
CBD chimeric protein can bind to the chitin beads and on-column intein-mediated cleavage 
of ficolin-B is induced by DTT addition (Manual Impact kit E6901). 
Intein ficolinB
fusion protein
Affinity 
Purification
 
Fig.  3.3: Schematic illustration of the IMPACT System. 
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3.1.1. Cloning of a ficolin-B expression construct in pTXB1 impact kit vector 
In order to clone the ficolin-B sequence into the pTXB1 prokaryotic expression vector, primer 
pairs (numbered from 1 and 2 in section 2.1.9) were designed to amplify the cDNA of ficolin-
B using cDNA derived from HoxB-8 cells (cDNA from HoxB-8 - neutrophil progenitor cells). 
These PCR product were first cloned into the pGEMT vector, which is an activated plasmid 
ready to accept PCR products as inserts. The primers also contained endonuclease 
restriction sites at the 5’ ends to further digest the pGEMT-ficolin-B vector with NdeI/SapI  
inorder to subclone the ficolin-B cDNA into the pTXB1 vector (Fig 3.4), which has been 
digested with the same enzymes.  
 
RT-PCR product Ficolin-B-
pGEMT 
Ficolin-B-
pTXB1
NdeI SapI
mFicolin-B (~950 bp)
fcnBNdeI                                   SapI
 
Fig. 3.4: Diagram describing the construction of the ficolin-B pTXB1 plasmid, pTXB1 
containing T7 promoter-driven system to achieve high levels of expression and tight 
transcriptional control in E. coli. The arrow head indicates the self-cleavage site of the intein 
which allows the release of the target protein (Ficolin-B) from the chitin-bound C-terminal intein 
tag.  
Briefly, based on the known mouse ficolin-B gene sequence (Gen-Bank Accession No. M 
070497) the specific primers for PCR amplification were designed to amplify the cDNA  
fragment containing the ATG of the endogenous. Appropriate restriction sites, absent in 
the target gene, are incorporated in the forward and reverse primers when a target gene 
is generated by PCR. Cloning into the NdeI and the SapI sites results in the fusion of the 
intein to the C-terminus of the ficolin-B protein, without any extra amino acids on the  
protein after cleavage of the intein tag. PCR was done as described in the materials and 
methods (Section 2.2.1.1.1). The amplification products were analyzed by electrophoresis 
on a 1.5% agarose gel stained with ethidium bromide (EtBr). A specific 1Kb PCR product 
was obtained (Figure 3.5). The amplification product (500 ng), digested with NdeI and 
SapI, was isolated from an agarose gel bands using Gel-Out kit (Promega).  
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Fig. 3.5: The PCR products of the target 
genes: DNA samples were separated on a 
1.5% (w/v) agarose gel containing EtBr Lane 
M: NEB (1Kb) DNA high range marker ready 
to use and lane 2 PCR product. Lane M, DNA 
marker and lane 1,2 PCR product of mficolin-
B. 
 
 
Prior to ligation into the pTXB1 vector, the vector was digested with restriction enzymes 
(NdeI/SapI) and was dephosphorylated by Calf intestinal alkaline phosphatase (CIAP) 
treatment to prevent religation. After ligation of E.coli XL1blue cells were transformed. 
Transformed E.coli colonies were screened by colony-PCR with the primers mentioned 
above. PCR products were analysed by DNA gel electrophoresis. Figure 3.6 shows that PCR 
of colonies 1 to 33,  amplified bands with a size of 950bp that correlated with the calculated 
size of ficolin-B cDNA. Lane (NC-negative control) showed no bands at the expected size 
indicating that these clones did not carry the vector containing the correct insert. 
 
Fig. 3.6: Colony PCR to quickly amplify and screen 
positive clones : Colonies containing a 950bp 
fragment cloned into the pTXB1 vector were grown on 
ampicillin plates at either single-copy or high-copy 
number were picked for PCR Screen. Colony PCR was 
performed using primers homologous to the ends of the 
cloning vector. Lane M, DNA size marker; The top panel 
shows clones 1 to 5. The resulting PCR fragments from 
the positive clones are ~950kb, as expected. NC, E.coli 
XL-1 Blue (negative control). 
 
 
Ficolin-B
(950 bp)
500
100
1000
Marker    PCR Product
(Bp)          1            2
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To check whether those clones giving positive results in the PCR screening indeed carried 
the insert of interest, a plasmid preparation of an overnight E.coli culture of every each 
individual colony was made. The plasmid DNA was digested with the restriction enzymes 
NdeI and SapI and loaded on a 1% (w/v) agarose gel containing EtBr. Figure 3.7 shows the 
restriction digestion of clone 4. The gel was run with the undigested plasmid DNA (Lane1), 
with single digestions (Lane 2,3) and double digestions (Lane4). The double digested 
(NdeI/SapI) clone 4 contained a DNA insert in the size of 950 bp matching the expected size 
for ficolin-B.  
 
 
 
 
Fig. 3.7: mficolin-B in pTXB1 vector SapI/NdeI 
control digest: Plasmid DNA  (Lanes 1 to 4) was 
digested with restriction enzymes SapI/NdeI and 
checked on a 1.5% (w/v) agarose gel containing 
EtBr. Lane M: NEB 100 bp DNA ladder marker; 
Lane1, Undigested control; Lane2, the digestion 
of pTXB1-ficolin-B recombinant with SapI; Lane3, 
the digestion of pTXB1-ficolin-B recombinant with 
NdeI; the digestion of pTXB1-ficolin-B 
recombinant with SapI/NdeI.  
 
Isolated plasmid DNA samples of the positive clone (clone 4) was verified by sequencing 
(Geneart Regensburg, Germany) using standard T7 primers. As the standard primers were 
not sufficient to obtain full-length sequences, internal primers were designed. Obtained 
sequences were matched with the mficolin-B sequence (NCBI Accession No.: M070497) by 
BLAST analysis (data not shown). 
3.1.2.  Expression and purification of intein-ficolin-B fusion protein 
3.1.2.1. Expression of the Intein-ficolin-B fusion protein 
In order to determine the expression of intein ficolin-B fusion protein, the vector containing 
the ficolin-B DNA was transformed into E.coli BL21 (DE3) pLysS cells and protein expression 
of ficolin-B over a time period of 4 hours was analysed. Expression was induced with two 
different concentrations of IPTG (0.1 and 0.4 mM) and protein expression over time was 
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detected by SDS-PAGE (Fig 3.8) and staining with Coomassie brilliant blue (Materials and 
Methods - section 2.3.1). 
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Fig. 3.8: Test expression of pTXB1-Ficolin-B recombinant protein: SDS-PAGE analysis of 
fusion proteins expressed in E.coli BL21 (DE3)pLys. Samples were collected at different 
timepoints (0 – 4hrs) after induction with 0.1 (Lanes 2,4,5) & 0.4mM (Lanes 3,6,7) IPTG and 
also samples representing the solubly expressed (Lane 5,7) and the insolubly expressed 
(Lane 2,3,4,6) protein fractions were collected.  All samples were separated by SDS-PAGE 
(10%) and the gel was stained with Coomassie brilliant blue to detect proteins. Lane M: 
Precision plus 4 -20% Tris-HCL gel SDS-PAGE marker. The arrow indicates the predicted 
electrophoretic mobility of intein-ficolin-B fusion protein (~62 kDa). 
The calculated size of recombinant ficolin-B including the intein-tag was ~62 kDa. Figure 3.8 
shows that the protein expression increased over the time course of 4 hours (Lanes 2h to 4h) 
as compared to the uninduced stage (Lane 1). Several proteins of lower as well as of higher 
molecular weight were detected. Prominent bands appeared, indicating proteins of a 
molecular weight of approximately 25 kDa and 35 kDa. These proteins represented putative 
degraded products of ficolin-B. A band in the range of ~62 kDa was visible in all lanes except 
for the uninduced protein fraction (before induc.). This band probably resulted from the 
recombinant ficolin-B protein. The majority of the proteins seemed to be insolubly expressed 
as there were more intense bands in this fractions (Lanes 2,3,4,6) as compared to the 
solubly expressed protein fraction (Lanes 5,7.) at the expected size of ~62 kDa as indicated 
by arrowhead. 
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3.1.2.2. Miniprep - Protein expression test for the Intein-ficolin-B fusion protein to 
check solubility    
To further investigate whether the intein-ficolin-B fusion protein was in the insoluble (pellet) 
or in soluble (supernatant) fraction, a miniprep expression test was done where the  bacterial 
sample collected was lysed and centrifuged to get it separated into insoluble and soluble 
sample fractions (Materials and Methods – Section 2.3.9). To monitor the protein expression, 
12 µL of the soluble and insoluble fractions as well as of each sample taken every hour were 
loaded on SDS-PAGE gels (10 or 12%), with Coomassie brilliant blue staining. The 
expression of proteins was monitored at different temperatures 30°C and 20°C at 0.1mM 
IPTG (Figure 3.9). The majority of the proteins seemed to be insolubly expressed as there 
were more intense bands in these fractions of pellet lysates (P) as compared to the solubly 
expressed protein fraction in the supernatant of the lysates (S) at the expected size of ~62 
kDa as indicated by arrow. Only a weak band was observed in the supernatant lysate (S) of 
the expected size of fusion proteins. 
A) Expression of pTXB1 Ficolin-B at 30°C  B) Expression of pTXB1 Ficolin-B at 20°C 
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Fig. 3.9: Solubility test expression of pTXB1-Ficolin-B recombinant protein: SDS-PAGE 
analysis of fusion proteins expressed in E.coli BL21(DE3)pLys. Samples were collected at 
different time points (Lane 1,2 non-induced; Lane 3,4 induced 2hrs, lane 5,6 induced 4hrs; 
lane 7,8 induced overnight) after induction with 0.1mM IPTG. The samples were lysed and run 
on gel representing the solubly expressed supernatant and the insolubly expressed pellet 
protein fractions.  All samples were separated by SDS-PAGE (10%) and the gel was stained 
with Coomassie brilliant blue to detect proteins. Lane M: Precision plus 4 -20% Tris-HCL gel 
SDS-PAGE marker. The other lanes were applied with pellet and supernatant lysates from 
non-induced and induced bacteria for 2hrs and 4hrs. 
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3.1.2.3. Western blot for the Intein-ficolin-B fusion protein  
To further confirm the presence of the ficolin-B protein, The expression of intein-tagged 
proteins over the time period of 4 hours was analysed by immunoblotting (Western blot and 
Dot blot). We analysed whether the weak bands of approximately ~62 kDa represented the 
protein of interest. We performed Western and dot blots to specifically detect CBD intein-
tagged proteins and ficolin-B protein. Samples separated by SDS-PAGE were transferred 
onto polyvinyl difluoride (PVDF) membrane. After saturation of non-specific binding sites the 
sheets were incubated with a rabbit anti-chitin antibody (A) and rabbit anti-ficolin-B antibody 
(B) (Figure 3.10). Detection was achieved by a secondary antibody, that was HRP-linked and 
the Lumigen™ detection reagent. 
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Fig.3.10: Immunoblot for the pTXB1-ficolin-B recombinant protein : Western blot analysis 
of fusion proteins expressed in E.coli BL 21 (DE3) p Lys. The same samples collected at 
different time points (0 – 4hrs) after induction with 0.1mM IPTG was used for blot analysis. The 
samples representing the solubly expressed supernatant) and the insolubly expressed pellet 
protein fractions as described for Fig.3.9 were separated by SDS-PAGE (10%), blotted onto a 
PVDF membrane and finally, detected with the Lumigen™ detection reagent and developed 
on a hyperfilm. Figure 3.10 A was detected with anti-chitin binding domain (CBD) antibody and 
Figure 3.10 B with anti-ficolin-B antibody. Lane M: Protein molecular weight marker; lane 1,2 
E.coli/pTXB1 ficolin-B uninduced pellet and supernatent as negative control; lane 3, 4 
E.coli/pTXB1 ficolin-B induced 2 Hrs pellet and supernatent for ; Lane 5,6 E.coli/pTXB1 
Ficolin-B induced 4 hrs pellet and supernatant; lane 7, recombinant ficolin-B as positive 
control. 
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3.1.2.4. Dot Blot for the Intein-ficolin-B fusion protein  
In order to confirm that the antibody is able to detect the native form of the recombinant 
protein, a dot blot assay was performed.  For dot blot analysis, different volumes of the 
protein samples (1.0, 2.5 and 5µl) were spotted on the membrane. Recombinant ficolin-B 
and ficolin-B fusion protein samples (pellet and supernatant) were detected with anti-CBD 
(Fig 3.11 A) and anti-ficolin-B (Fig 3.11 B) and DS2 cells purified ficolin-B as positive control 
and PBS as negative control.  
 
Pellet             Supernatant 
1µl         2.5µl           2.5µl 5µl 
A) Antibody: Rabbit anti-Chitin binding domain (CBD)           B) Antibody: Rabbit anti-ficolin-B 
Non-Induc. 1µg         3µg       5µg    rFcn-B 
cells
Pellet             Supernatant 
1µl         2.5µl           2.5µl 5µl 
 
Fig. 3.11: Dot blot for the detection of non-reduced ficolin-B with the rabbit anti-chitin binding 
domain (CBD) and rabbit anti-ficolin-B antibody. Recombinant ficolin-B was spotted on a 
nitrocellulose membrane at the specified volumes and incubated with the a anti-CBD antibody 
(Figure-A) and anti-ficolin-B antibody (Figure-B) in a 1:2000 dilution. An HRP conjugated anti-
rabbit antibody was used for detection. Non-induced cells  was spotted as a negative control.  
Both the Western blot and dot blot analysis showed that the protein was only to be detected 
in the insoluble fractions. 
Protein expression at lower temperatures decreases the rate of protein expression. This 
decreased rate of protein synthesis results in an enhanced capacity to fold proteins correctly. 
We induced protein expression by addition of 0.1 mM IPTG and incubated the cells at 16°C 
as E. coli cells still grow and express proteins at this temperature. Finally, we checked 
protein expression over the investigated time course of expression by SDS-PAGE and 
staining with Coomassie brilliant blue.  We also tried a short induction time with very low 
IPTG (0.05mM) to check for the expression of proteins (data not shown).   
Neither expression at 16°C nor short induction time  led to improved expression of the ficolin-
B protein. So we decided to continue with a large scale protein expression under standard 
conditions to purify the protein. We thought the expression of proteins under large scale 
conditions might help to get some proteins expressed in the soluble form and if not decided 
to purify the proteins from inclusion bodies since we already showed in SDS-PAGE and 
Western blot the expression of proteins in the insoluble fraction. 
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3.1.3. Large scale purification of Intein-ficolin-B fusion protein 
3.1.3.1. Purification of pTXB1-ficolin-B fusion protein from cell lysates 
The expression of recombinant proteins with intein fusion tags is widely used to facilitate their 
purification from a variety of prokaryotic expression systems. The main concept works via the 
intein-mediated protein purification with a self-cleavable affinity tag. A target protein is fused 
to the C-terminus of a modified protein splicing element (intein) which is in turn fused to an 
affinity tag (CBD). The fusion protein from a crude cell extract is purified by adsorption to a 
chitin affinity column. The intein is then induced to undergo on-column self-cleavage by a 
chemical reagent (DTT). The target protein is specifically released from the column and 
eluted as a pure protein (Fig 3.12) (Materials and Method – Section 2.4.1.1). 
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B) Western blot 
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Fig. 3.12: Single column native purification of recombinant proteins from E. coli using 
pTXB1 vectors. A) Schematic representation of the expression and purification of ficolin-B 
using a pTXB1 vector. Samples taken from different steps during the expression and 
purification procedures were separated by SDS-PAGE and the gel was stained with 
Coomassie blue. Lanes: M, protein molecular weight standards (kDa, NEB); 1, uninduced cell 
extract; 2, induced cell extract; 3,4, flow through (F.T.) from the load. After loading, the column 
is washed with column buffer until the protein content of the eluate reached a minimum; 5,6, 
flow through from the quick DTT flush; 7–9, the first three fractions of the elution after the 4°C 
overnight (o.n.) incubation in the presence of DTT; 10, a fraction from the SDS elution (to look 
for cleavage efficiency).11, rficolin-B as positive control. B) Western blot analysis of fusion 
proteins expressed in E.coli BL 21 (DE3) p Lys. The large scale purified samples were tested 
with rabbit anti-CBD antibody (1) and rabbit anti-ficolin-B antibody (2). The samples as 
described for Fig.3.12A were separated by SDS-PAGE (10%), blotted onto a PVDF membrane 
and finally, detected with the Lumigen™ detection reagent and developed on a hyperfilm. Lane 
M: Protein molecular weight marker; lane 1,2 E.coli/pTXB1 ficolin-B uninduced sample and 
induced sample; lane 3, ficolin-B elution fractions,lane 4, ficolin-B elution fractions 
concentrated with ultrafilter;lane 5, sample beads after cleavage; lane 6, recombinant ficolin-B 
as positive control. 
However, these data further confirmed that even the expression of proteins under large scale 
conditions had no effect on the production of proteins into the supernatant fraction.  
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3.1.3.2. Purification of the Intein-ficolin-B protein from inclusion bodies  
Since we observed a good expression of proteins in the insoluble fraction, we tried to purify 
the ficolin-B proteins from the inclusion bodies. When purifying a protein that may be 
insoluble, several factors have to be considered: 
1. The binding efficiency of the intein-tag to the chitin resin is lower at 4 M urea or higher  
2. The intein-mediated cleavage reaction may be carried out at 0 - 2 M urea  
3. The higher the urea concentration, the better the chance to solubilize a target protein. 
However, the cleavage reaction should be performed in 0 - 2 M urea  
Using a standard protocol for chitin chromatography and using the cleavage conditions 
recommended for the specific intein-tag (Materials and Methods – Section 2.2.2) we eluted 
the protein and analyzed both the eluate and chitin beads for cleavage and protein solubility 
(Fig 3.13). 
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B) Western blots 
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Fig. 3.13. Single column purification of recombinant proteins from Inclusion bodies A) 
Schematic representation of the expression and purification of ficolin-B using a pTXB1 vector. 
The pellets are lysed with guanidine hydrochloride and dialysed against different 
concentrations of urea. Samples taken from different steps during the expression and 
purification procedures were separated by SDS-PAGE and the gel was stained with 
Coomassie blue. Lanes: M, protein molecular weight standards (kDa, NEB); 1, uninduced cell 
extract; 2, induced cell extract; 3, lysed pellet and 4, supernatant. After denaturation with 
guanidine chloride and slow renaturation with urea, the column is washed with column buffer 
until the protein content of the eluate reached a minimum; 5, flow through from the quick DTT 
flush; 6, the fractions of the elution after the 4°C overnight (o.n.) incubation in the presence of 
DTT; 7, a fraction from the SDS elution (to look for cleavage efficiency). B) Western blot 
analysis of fusion proteins expressed in E.coli BL 21 (DE3) p Lys. The large scale purified 
samples were tested with rabbit anti-CBD antibody (1) rabbit anti-ficolin-B antibody (2). The 
samples as described for Fig.3.13A were separated by SDS-PAGE (10%), blotted onto a 
PVDF membrane and finally, detected with the Lumigen™ detection reagent and developed 
on a hyperfilm. Lane M: Protein molecular weight marker; lane 1,2 E.coli/pTXB1 ficolin-B 
uninduced sample and induced sample; lane 3, ficolin-B elution fractions,lane 4, ficolin-B 
elution fractions concentrated with ultrafilter;lane 5, sample beads after cleavage; ; lane 6, 
recombinant ficolin-B as positive control. 
The conclusion from the attempts with the IMPACT kit expression system is that ficolin-B 
shows  a good expression, but the protein is insoluble and remains aggregated with the chitin 
beads even upon purification. Ficolin-B from the intein fusion protein is not cleaved-off as 
ficolin-B still seems to be associated with chitin.  
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3.2. Binding studies 
3.2.1. Binding studies of the intein-ficolin-B fusion protein from E.coli lysates to 
chitin 
It was theoretically possible that the intein-ficolin-B fusion protein loaded onto the chitin-
column would be properly cleaved, but that the ficolin-B itself would re-bind to the chitin by its 
carbohydrate recognition site. Therefore, as a next approach, I wanted to test whether ficolin-
B has binding affinity for chitin.  It was shown that human ficolins as well as mouse ficolins 
share binding specificity for N-acetylglucosamine (GlcNAc) (Le et al., 1998 ; Fujimori et al., 
1998 ; Teh et al., 2000). Therefore, It was of particular interest to assess the ficolin-B 
specificity for this molecule. The assay was performed as Fujimori and co-workers reported 
in 1998 for ficolin-A. 
DS2 expressed ficolin-B on GlcNAc agarose beads served as a positive control and non-
induced intein-ficolin-B was used as a negative control. But no binding activity was observed 
with the E.coli expressed material (data not shown). Since the purification of recombinant 
ficolin-B from E.coli BL21(DE3)pLysS cells did not result in soluble ficolin-B, we tested crude 
bacterial lysates of DS2 insect cells that had been transfected with the vector containing the 
ficolin-B insert for their ability to bind to GLcNAc agarose or Chitin (Fig 3.14).  
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Fig. 3.14. Binding of ficolin-B to various ligands: Plates were coated with either BSA, 
AcBSA or chitin beads, as indicated. Ficolin-B binding (at different concentrations) was 
detected by ELISA. The binding was tested under different buffer conditions (e.g. Ca2+ or 
EDTA) to know whether the binding is Ca2+ dependent. DS2-ficolin-B binding to AcBSA 
served as a positive control and AcBSA, BSA and chitin in the absence of ficolin-B as  
negative controls. Binding was detected with monoclonal antibodies directed aganist the 
ficolin-B protein.The absorbance values measured at 450nm.  
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We also tested the binding activity to chitin on the A.fumigatis cell wall (kindly gifted by Prof. 
Dr. Frank Ebel, Max-von-Pettenkofer-Institut, München). These experiment however, did not 
lead to reproducible results. These experiments were performed in collaboration with Katja 
Hunold and Dorothea Weber-Steffens. 
The binding studies show that there was an dose-dependent binding of ficolin-B to chitin and 
that the binding was Ca2+ independent. EDTA had no significant effect on ficolin-B binding 
to chitin. Binding of ficolin-B to A.fumigatis could not be shown due to technical problems. 
3.3. Cloning and expression of ficolin-B with His-tagged vector 
Since the intein vector system failed to express the fusion protein in a soluble form, we 
decided to continue with a His-tagged vector system which is a more convenient system for 
purification of proteins by affinity chromatography. We analysed mficolin-B protein 
expression with an N-terminal His tag vector (pET28) and a C-terminal His tag vector 
(pPROEXHTb).  
3.3.1. Cloning of ficolin-B with N-terminal and C-terminal His-tagged vectors 
Based on the known mouse ficolin-B cDNA sequence (Gen-Bank Accession No. M 070497) 
the specific primers (numbered from 3 and 4 in section 2.1.9) for PCR amplification were 
used. Appropriate restriction sites, absent in the target gene were incorporated in the forward 
and reverse primers. PCR was done as described in the materials and methods (Section 
2.2.1.1.1). The amplification products were analyzed by electrophoresis on a 1% agarose 
gels stained with ethidium bromide (Fig 3.15). The amplification product (500ng), digested 
with BamHI and XhoI, after isolation using Gel-Out kit (Promega).  
 
 
 
 
 
 
 
 
 
3. Results 
71 
pProExHtb
pET28a
1000Bp
1000Bp
Ficolin-B
Ficolin-B
500Bp
500Bp 
M M
 
Fig. 3.15: mficolin-B in pET28 and pProExHtb vector: Plasmid DNA  (Fig. left and right) 
was digested with restriction enzymes BamHI/XhoI and checked on a 1.5% (w/v) agarose gel 
containing EtBr. Lane M: NEB 100 bp DNA ladder marker and the digestion of pET28 and 
pProExHtb ficolin-B recombinant with BamHI/XhoI.  
3.3.2. Miniprep for protein expression as a test to check solubility    
(Protocol followed as described for GST section 3.2.3.1) 
1) N-Terminal His-tag protein expression         2) C-Terminal His-tag protein expression   
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Fig. 3.16: Solubility test expression of N- and C-terminal ficolin-B recombinant protein: 
SDS-PAGE analysis of fusion proteins expressed in E.coli BL21 (DE3)pLys. Samples were 
collected at different time points (0 – overnight) after induction with 0.1mM IPTG. The samples 
were lysed and run on gel representing the solubly expressed supernatant) and the insolubly 
expressed pellet protein fractions.  All samples were separated by SDS-PAGE (10%) and the 
gel was stained with Coomassie brilliant blue to detect proteins. Lane M: Precision plus 4 -20% 
Tris-HCL gel SDS-PAGE marker. The other lanes were applied with pellet and supernatent 
samples from non-induced and induced for 2hrs, 4hrs and overnight. The arrow indicates the 
predicted electrophoretic mobility of His-ficolin-B fusion protein. 
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However the His-tagged protein expression again was only detected in the insoluble fractions 
(Fig 3.16). The different expression vector system showed that the ficolin-B cannot be 
expressed in the soluble form which might be due to its complex higher oligomers and 
multimers that might be dependent on glycosylation which cannot happen in E. coli. 
3.4. Cloning and expression of ficolin-B with GST tagged vector 
3.4.1. Cloning of a ficolin-B expression construct in pGEX vector   
As a next approach, we decided to go for the GST expression vector system. The use of 
GST as a fusion tag is desirable  because it can act as a chaperone to facilitate protein 
folding, and frequently the fusion protein can be expressed as a soluble protein. Here we 
used a modified pGEX vector which has a TEV cleavage site (Fig 3.15). The advantage of 
TEV (Tobacco etch virus) is  its specifity  and that the cleavage efficiency is not much altered 
by salt or temperature . 
 
 
 
Fig. 3.17. Diagram describing the construction of the recombinant expression plasmid 
pGEX4T-1-NTEV.The arrow indicates the cleavage sit of TEV which allows the release of the 
target protein from the tag. 
Based on the known mouse ficolin-B gene sequence (Gen-Bank Accession No. M 070497) 
specific primers (numbered from 3 to 4 in section 2.7) for PCR amplification were used as 
described in (section 2.2.1.1.1). BamHI and XhoI restriction sites absent in the target gene 
were incorporated in the forward and reverse primers. Cloning into the BamHI and the XhoI 
sites will place the ficolin-B cDNA in frame with the GST coding sequence (Fig 3.17). PCR 
 
Thrombin   mFicolin-B (~950 bp)
BamHI/XhoI
pGEX-4T-1-Ficolin-B
6035bp
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was done as described in the Materials and Methods (Section 2.2.1.1.1). The amplification 
products were analyzed by electrophoresis on a 1% agarose gels stained with ethidium 
bromide. A  Specific 950-bp PCR product was obtained. (Figure 3.18). The amplification 
product (500ng), digested with BamHI and XhoI, was isolated from an agarose gel bands 
using Gel-Out kit (Promega).  
 
  
 
Fig. 3.18: mficolin-B in pGEX vector: Plasmid DNA  
(Clone 4, 6) was digested with restriction enzymes 
BamHI/XhoI and checked on a 1.5% (w/v) agarose gel 
containing EtBr. Lane M: NEB 100 bp DNA ladder marker 
and the digestion of pGEX ficolin-B recombinant with 
BamHI/XhoI 
 
 
3.4.2. Expression of the GST ficolin-B fusion protein  
In order to determine wether the expression of GST ficolin-B fusion protein was either in the 
insoluble (pellet) or in the soluble (supernatant) fraction, an expression test was done with 
bacteria collected by centrifugation (as described in section 3.1.2.1) followed by a miniprep 
expression where the bacterial sample collected was lysed and centrifuged to get it 
separated into soluble and insoluble fractions (as described in section 3.1.2.2).  
To monitor protein expression over time, 12 µL of the soluble and insoluble fractions as well 
as of each sample taken every hour were loaded on SDS-PAGE gels (10 or 12%), with 
Coomassie brilliant blue staining. The expression of proteins was monitored at temperatures 
30°C and at 0.1mM IPTG (Figure 3.19). 
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Fig. 3.19: Test expression of pTXB1-ficolin-B recombinant protein: SDS-PAGE analysis 
of fusion proteins expressed in E.coli BL21(DE3)pLys. Samples were collected at different time 
points (0 – 4hrs and Overnight) after induction with 0.1 mM IPTG (Gel 1) and also samples 
representing the solubly expressed and the insolubly expressed (Gel 2) protein fractions were 
collected.  All samples were separated by SDS-PAGE (10%) and the gel was stained with 
Coomassie brilliant blue to detect proteins. Lane M: Precision plus 4 -20% Tris-HCL gel SDS-
PAGE marker. The arrow indicates the predicted electrophoretic mobility of GST-ficolin-B 
fusion protein. 
However, also the GST fusion protein expression was only in inclusion bodies and neither 
expression at different temperatures nor at different IPTG concentrations had any effect on 
protein expression in the supernatant fraction. 
3.5. Cloning and expression of the collagen domain of ficolin-B fused to  GST  
As our attempts did not lead to successful high level expression of the full-length ficolin-B, we 
decided to individually express the conserved regions of the ficolin-B. The gene sequence 
alignment of all ficolins and MBL had shown the presence of a putative MASP binding motif 
residing at  the collageous domain (Wallis et al., 2007). For this purpose we cloned the 
collagen domain (180 bp) of ficolin-B into the pGEX-4T-1 vector and expressed it in E.coli 
BL21(DE3)pLysS cells ( as shown in fig.3.20) 
PCR was done as described in Materials and Methods – (Section 2.2.1.1.1).  
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Fig. 3.20: The PCR products of the target genes : A) Domain organisation of mouse ficolin-
B. The collagenous domain (*) is shown as two segments, which are separated by the 
interruption in the Gly–Xaa–Yaa collagen repeat (Wallis., 2007). Arrows show potentially 
flexible regions. The aligned sequences of the collagenous domain of ficolin-B is shown below 
B) DNA samples were separated on a 1.5% (w/v) agarose gel containing EtBr Lane M: NEB 
(1Kb) DNA high range marker ready to use and lane 2 PCR product. 
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3.5.1. Miniprep for protein expression as a test to check solubility    
To further investigate whether GST-Collagen of ficolin-B fusion protein expression was in the 
insoluble or in soluble fraction, a miniprep expression test was done where the  bacterial 
sample collected was lysed and centrifuged to get it separated into pellet and supernatant 
(as described in section 3.1.2.2). The expression of proteins was monitored at temperature 
30°C and at 0.1mM IPTG (Figure 3.21). 
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Fig. 3.21: Solubility test expression of pTXB1-ficolin-B recombinant protein: SDS-PAGE 
analysis of fusion proteins expressed in E.coli BL21(DE3)pLys. Samples were collected at 
different time points (0 – overnight) after induction with 0.1mM IPTG. The samples were lysed 
and run on gel representing the solubly expressed supernatant and the insolubly expressed 
pellet protein fractions.  All samples were separated by SDS-PAGE (10%) and the gel was 
stained with Coomassie brilliant blue to detect proteins. Lane M: Precision plus 4 -20% Tris-
HCL gel SDS-PAGE marker. lane 1,2 uninduced sample; lane 3, 4, -2 hrs induced sample; 
lane 5, 6, -4 hrs induced sample; lane 7, 8, -overnight induced sample; lane 9,  GST protein as 
positive control. 
The GST collagen domain of ficolin-B fusion protein can be expressed in the soluble form 
(supernatant).  
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Mutational analysis of mouse ficolin-B 
and biochemical characterization                       
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3.6. Mutational analysis of ficolin-B specificity and biological function 
The goal of this work was to look, if any mutational changes in the collageous domain of 
ficolin-B will lead to a change  of binding of mouse ficolin-B to MASP2 and modulate or affect 
activation of the lectin pathway of the complement system. Here with ficolin-B, we mutated 
the glutamic acid (in X (E72A) position of putative MASP binding motif) to alanine (which is a 
common amino acid in other lectins). 
 
Girija et al, 2007
Collageous domain Carbohydrate recognition domain
MASP interaction domain
mficolin-B
A)
B)
 
Fig. 3.22: Domain organization of the ficolins. A) Aligned sequences of the collagenous 
domains of ficolins. B) The putative MASP-binding motif is shaded. Lysine residues within the 
Y position of the Gly-X-Y repeat are underlined. All such residues are at least partially 
hydroxylated and glycosylated. Glutamic acid (E) (Yellow box) in the mouse ficolin-B is 
mutated and replaced by alanine. 
3.6.1. Generation of ficolin-B expression constructs 
The ficolin-B gene contains a 942bp-base pair (bp) open reading frame (ORF) encoding 314 
amino acids. In order to clone the sequences into the pMT/BiP/V5-His A – Hygro expression 
vector, primer pairs (numbered 6 to 7 in materials and methods section 2.7) were designed 
to amplify the mficolin-B cDNA without endogenous leader peptide region because the 
plasmid pMT/BiP/V5-His A contains the Drosophila BiP signal sequence for secretion of the 
recombinant protein into the culture medium. Therefore, a 882 bp fragment was amplified by 
PCR from spleen cDNA. The fragment was first cloned
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is an activated plasmid ready to accept PCR products as inserts, to generate the “TOPO-
ficolin-B” constructs. Since the primers also contained endonuclease restriction sites at the 5’ 
ends these constructs were further digested with BamHI/XhoI and the ficolin–B cDNA was 
subcloned into the pMT/BiP/V5-His A –Hygro expression vector, which was previously 
digested with the same enzymes to generate the constructs called  “pMTA-Hygro-ficolinB”. 
Figure 3.23 shows a scheme of the described cloning process. The resulting expression 
constructs were evaluated by restriction analysis and sequenced to confirm that the inserts 
were cloned in-frame with the V5/His-tags and lack any mutations before proceeding to 
transfection. Johann Röhrl is acknowledged for the pMT-pCoHygro expression construct. 
 
Ficolin-B
pMT/Bip/V5-HisA+pCoHygro 
(6300 bp)
NarI NarI
PmeI PmeI
pMT/Bip/V5-HisA+Ficolin-B+pCoHygro 
(7300 bp)
 
Fig. 3.23: Scheme for the cloning of mficolin–B genes into the pMT/BiP/V5-His A-Hygro 
expression vector. The ficolin–B genes were amplified by PCR, constructs were then 
digested with BamHI/XhoI and further subcloned into the pMT/BiP/V5-HisA –Hygro engineered 
expression plasmid. AmpR: ampicillin resistance gene; LacZ: α-fragment of the ß-
galactosidase gene; MCS: multiple cloning site; P Lac: LacZ promoter; P MT: metallothionein 
promoter; SV40 pA: Simian virus 40 polyadenylation signal.  
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3.6.2. Site-directed Mutagenesis   
Mutations (E72A) were constructed using the QuickChange Site-directed Mutagenesis kit 
(Stratagene) following the instructions provided by the manufacturer. Primers were designed 
as shown in table 1.The mutations were verified by DNA sequencing. pMT/BiP/V5-His A - 
Hygro (Ficolin-B fusion full length) was used as the template.  
 
Table 1. Primers used for Site directed mutagenesis of pMT-ficolin-B-pCoHygro 
 
Mutation name                                                                Primer sequence (5´to 3´) 
E72A                                                   cttcctggaattcctggaaaagcaggaccaactggacccaaagga 
Introduced sites of mutagenesis are in bold and underlined. Mutations were done taking the 
pMT-ficolin-B-pCoHygro (full length) as template. 
        
3.7. Biochemical characterization of the recombinant ficolin-B  
3.7.1. Reducing and non-reducing SDS-PAGE 
We looked for the oligomerization of ficolin-B expressed in DS2 cells by SDS-PAGE. For this 
purpose ficolin-B was separated by SDS-PAGE (10% gel) under reducing (Fig.3.24 A) and 
non-reducing (Fig.3.24 B) conditions. Then immunoblot analysis was performed using a 
polyclonal rabbit anti-ficolin-B antiserum. 
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Fig. 3.24: Oligomerization of mficolin-B in DS2 cells: Purified ficolin-B was separated by 
SDS-PAGE (10% gel) under reducing (A) and non- reducing (B, C) conditions. Then 
immunoblot analysis was performed using rabbit anti-ficolin-B antiserum. Molecular weight 
markers are indicated. 
Purified ficolin-B migrated  as  a double  band  on  SDS-polyacrylamide  gels under reducing 
conditions, with apparent molecular masses of 35 and 36 kDa (Figs.3.24A). Higher oligomers 
of ficolin-B were observed in the non-reducing conditions (3.24B). 
3.7.2. Analytical gel filtration 
In order to analyze the role of the multimerization in ficolin-B for effective biological activity, 
recombinant ficolin-B produced by DS2 cells was used for gel filtration analysis. I analysed  
two types of ficolin-B: one called  “Old ficolin-B” which was produced a year before and the 
other one is “Fresh ficolin-B” which was produced immediately before the experiment. 
Fig.3.25 shows the elution profiles obtained for the two recombinant ficolin-B preprations.  
Compared  to  the  elution  profile  of  standard  molecular weight  marker  on  the  superdex  
200  gel  filtration  column,  the  majority  of “Fresh ficolin-B”  migrated with an apparent 
molecular mass of 200-36 kDa. 
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Fig.3.25: Gel filtration of ficolin-B on a Superdex-200 column. The elution positions of 
monomers (2), and tetramers (1) of mouse  ficolin-B  are  indicated. Elution positions (3,4) 
might be the  degraded or proteolized products of ficolin-B. Blue elution curve, Fresh ficolin-B; 
pink elution curve, Old ficolin-B; Masses of molecular weight standards: 12.4 kDa. cytochrome 
c; 29 kDa, carbonic anhydrase; 66 kDa, bovine serum albumin; 200 kDa, b-amylase. 
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The elution profile clearly shows that the “Fresh ficolin-B” elutes as monomers (peak 2) and 
tetramers (peak 1) wheras the “Old ficolin-B”, shows a small peak of monomers (peak 2) and 
more of the degraded or proteolized products of ficolin-B (peaks 3,4). From the results it 
seems that the “old ficolin”  is degraded. 
3.8. Biochemical and functional characterization of the mouse ficolin-B mutant 
Since wild type ficolin-B and mutant ficolin-B expression took longer than expected, I took the 
supernatant of DS2 cells expressing the protein and analyzed the biochemical and functional 
characteristics of the ficolin-B. The following experiments were performed in collabration with 
Katja Hunold and Dorothea Weber-Steffens. 
3.8.1. Dot blot 
As a first step we performed a dot blot assay to check if the V5-HRP antibody could equally 
detect the wild type and mutant ficolin-B.  
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Fig. 3.26: Dot blot for the detection of wild type mficolin-B and mutant (supernatants) 
with the anti-(V5) tag antibody. A) Recombinant wildtype ficolin-B and mutant (supernatant) 
was spotted on a nitrocellulose membrane at the indicated volumes and incubated with the 
anti-(V5) tag antibody. DS2 expressed mBD14 was spotted as a negative control. B) 
Recombinant wild type ficolin-B and mutant (supernatant) was spotted on a nitrocellulose 
membrane for a dose response and incubated with the anti-(V5) tag antibody. DS2 expressed 
mBD14 was spotted as a negative control. 
For dot blot analysis, we also used supernatants from wild type ficolin-B spotted on the 
membrane. Mutant as well as wild type ficolin-B protein was detected by anti-(V5) tag 
antibody (Fig 3.26A). DS2 cells purified ficolin-B was a positive control and mBD14 was used 
as negative control. We checked in dot blot analysis different volumes of wild type and 
mutant ficolin-B supernatant with anti- (V5) tag antibody (Fig 3.26B) and used purified 
recombinant ficolin-B as positive and DS2 expressed mBD14 as negative control. 
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The dot blot confirmed the presence of the wild type and mutant ficolin-B protein detected by 
the ani-(V5) tag antibody. 
3.8.2. Western blot 
Ficolin-B is a oligomeric protein (Erickson et al., 1997). To further look for the oligomerization 
difference between wild type and mutant ficolin-B, the supernatant of the mutant protein was 
analysed by Western analysis. We performed reduced and non-reduced gel runs that was 
followed by Western blot to detect the difference in oligomerization of wild type and mutant 
ficolin-B. Samples separated by SDS-PAGE were transferred onto polyvinyl difluoride 
(PVDF) membrane. After saturation of non-specific binding sites the membrane were 
incubated with anti-(V5) tag antibody (Figure 3.27). 
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Fig.3.27: Immunoblot for the wild type and mutant mficolin-B protein : Western blot 
analysis of the wild type and mutant supernatant proteins expressed in DS2 cells A) shows the 
reducing gels and B) shows the non-reducing gels. Samples were separated by SDS-PAGE 
(7.5%), V5 tagged proteins detected by the anti-(V5) tag antibody.  
Western blot analysis showed that there was no difference in oligomerization between the 
wild type and mutant ficolin-B proteins. 
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3.8.3. ELISA 
Mouse ficolin-A and ficolin-B bind to GlcNAc and GalNAc. Ficolin-B, like M-ficolin, 
additionally recognizes sialic acid residues (Endo et al., 2005). As a next step we tested the 
binding activity to AcBSA with wildtype and mutant ficolin-B (Fig. 3.28). The test was done in 
the same way as shown in (Fig.3.14). 
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Fig.3.28. Binding of wild type and mutant ficolin-B to AcBSA: Plates were coated with 
AcBSA (10μg/ml). Wild type and mutant ficolin-B (supernatant) binding (at the different 
dilutions as indicated) was detected by ELISA. The binding buffer condition was 5mM 
Ca2+/TBST. Binding was detected with anti- (V5) HRP antibodies (1:5000 dilution).  
The binding study shows that there was no difference in binding to AcBSA of mutant ficolin-B 
when compared to wild type ficolin-B...............……………………………………………………. 
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4. Discussion 
Ficolins are becoming more important in innate immunity as they are shown to have many 
functions. Ficolins activate the complement system through their association with MASPs 
which in turn leads to pathogen phagocytosis, aggregation, and lysis.  
The first part of my project was to generate a tag-free recombinant ficolin-B in order to further 
characterize the protein and gain insights into its functions. Therefore, It was important to find 
a good expression system. An empirical approach is often necessary to find the best 
expression system for a protein of interest. Though the aim was to produce a tag-free ficolin-
B recombinant protein, comparison of the E.coli system with the DS-2 cell system clearly 
showed the advantages and problems of each system.  
Among the many systems available for heterlogous protein production, the use of the gram-
negative bacterium E.coli is widely used because of its ability to grow rapidly and at high 
density on inexpensive substrates. It is genetically well-characterized and available with an 
increasingly large number of cloning vectors and mutant strains. Moreover, the quality of the 
final product is higher than that of any non-recombinant method. With the DS-2 system 
(already an established system in our lab), the cells grow slow with low yields, but the main 
advantage is that they produce proteins with a glycosylation pattern similar to mammalian 
proteins. 
The recognition between protein partners is a fundamental molecular mechanism by which 
proteins execute their biological functions. In the second part of my project, I used some 
biochemical approaches to study the molecular recognition mechanisms between proteins to 
study their biological functions. 
To rationalize the results, I will discuss the two parts of the projects separately. 
4.1. Expression and purification of the ficolin-B-intein fusion protein from E.coli 
4.1.1. IMPACT kit for the production of  tag-free recombinant proteins 
The first aim of the present work was the production of recombinant ficolin-B by using the 
IMPACT kit system. We used this novel protein purification IMPACT system, because, it has 
several distinct advantages. It is rapid, and yields are comparable to those obtained by other 
expression methods. The IMPACT system utilizes the controlled C-terminal cleavage activity 
of the protein splicing elements (termed inteins) which can lead to better expression of 
proteins without the use of proteases. It can separate the target protein from the affinity tag in 
a single chromatographic step without any vector derived amino acids (Evans, T.C., et al. 
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(1998). The system has a chitin binding domain (CBD) incorporated which has extremely 
high affinity for the chitin beads, allowing better purification of fusion proteins (Chong et al., 
1997). High salt concentration of detergents can be used during washing steps which will 
reduce non-specific binding, thus increasing purity (Szweda et al., 2001). A recent report has 
shown a successful intein-mediated expression and purification as an effective approach in 
the study of β-defensins (Diao et al., 2007). 
For our experiments, we amplified cDNA from HoxB8 cells encoding full length mouse ficolin-
B and cloned it into the PTXB1 vector (C-terminus IMPACT vector; Fig 3.7). Cloning at the C-
terminus of the vector will result in a better expression of the protein. The target protein is 
fused at its C-terminus to a self-cleavable intein tag (~28 kD) that contains the (CBD, ~6 
kDa) allowing for affinity purification of the fusion precursor on a chitin column.   
4.1.2. Analysis of differential expression for the intein-ficolin-B fusion protein 
Next, we tried to optimize the expression conditions for ficolin-B under different conditions 
including low-temperature, IPTG, and induction time (Fig 3.8). Intrestingly, we were able to 
see a good expression of the ficolin-B protein as revealed by the SDS-PAGE, but the 
expression at the expected size (~62kDa) was seen only in the insoluble fraction. We could 
not detect any leaky expression in the post-induction sample, which further demonstrates a 
controlled high level induction by the T7 expression system. Gadgil et al., 2005 had reported 
that lower temperatures have the advantage of decreasing the growth rate of bacteria, which 
indirectly facilitates correct protein folding and brings the expression of protein in the soluble 
fraction. Since the expression was only in the insoluble fraction, we tried to bring the 
expression in the soluble form with different approaches like short time induction, low IPTG, 
or lowering the temperature (data not shown). Unfortunately a combination of these 
approaches was unable to induce sufficient levels of protein in the soluble fraction. It has 
been shown in this work that 0.1mM IPTG is used to induce expression and slightly higher or 
lower concentration of IPTG or temperature did not have any impact on the production of the 
protein in the soluble fraction (Fig 3.9). The majority of the protein seemed to be insolubly 
expressed as seen with more intense bands with the pellet lysates at the expected size of 
the fusion protein (~62kDa) and rapid expression of recombinant ficolin-B protein resulted in 
accumulation of insoluble protein. Arie et al., 2006 have reported that the protein aggregates 
into inclusion bodies in either the cytoplasm or the periplasm, depending on the target protein 
being produced. However in this case, it might be that ficolin-B being a complex oligomeric 
protein might depend on an increased capacity of post-translational modifications to express 
the protein in the soluble fraction. Production of “complex proteins” that require further 
modification or secretion in the soluble fraction is a challenging task. Miroux and Walker 
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(1996) reported that by over-expression plasmids themselves are intrinsically toxic to E.coli 
strain BL21(DE3). In order to check that point, I also tried to express ficolin-B in the Rosetta 
strain which is said to be a good expression strain for the mammalian proteins. But, 
nevertheless the expressed protein remained insoluble. 
4.1.3. Protein identification 
Although I could detect the intein fusion protein by coomassie brilliant blue by its expected 
size (~62kDa), I wanted to confirm the same through the immunoblot detection system 
specific for CBD intein-tagged proteins and ficolin-B protein. Both the Western blot (Fig 3.10) 
and dot blot (Fig 3.11) again confirmed the nature of the fusion protein and that it was 
insoluble. I also used Bradford and Lowrys assays to measure the lysate concentrations, but 
accurate determination of protein concentrations could not be done (data not shown). 
4.1.4. Purification with the IMPACT system 
Nevertheless, I tried large scale purification of proteins with the IMPACT system, but was not 
able to purify detectable amounts of the protein. The large scale purification again confirmed 
by SDS-PAGE and Western blot (Fig 3.12) that the protein was only insolubly expressed. I 
also tried to purify the protein from inclusion bodies. First I tried with 8M urea as denaturating 
agent, but this procedure was not successful to denature the protein completely (data not 
shown). So as a next step, I tried to lyse with a harsh denaturant like 7 M guanidine-HCl and 
the data (Fig 3.13) shows that the protein tends to get aggregated at the chitin beads. The 
inclusion bodies are mainly composed of unfolded and misfolded polypeptides that have 
aggregated as a result of non-specific interactions. The results presented here are in strong 
agreement with results reported from previous research, which demonstrated by gel filtration 
heterogenous oligomers due to improper folding of ficolins (Erickson et al., 1997). Bhuyan, 
2002 has shown that, in contrast to urea, guanidine-HCl is a highly charged molecule, hence 
the electrostatic interaction of guanidine-HCl and the E.coli protein with this high overall 
charge could explain the effect of strong aggregation. Gracia-Fruitos et al., 2005 have 
reported that inclusion bodies are composed of proteins that are correctly folded and have 
biological activity. Maybe in this case, a small part of the polypeptide of ficolin-B gets purified 
from inclusion bodies to be biologically active and that again strongly associates with the 
chitin beads in the chitin column. I also tried by increasing the concentration of cleavage 
buffer dithiothreitol (DTT) and cleavage time, but in vein.  Ficolin-B as a multimeric protein is 
composed of inter- and intra-chain disulphides and may not be possible for protein 
expression in the reducing cytoplasm of wild-type E.coli which results in aggregation. In 
addition E.coli does not have the ability to support all post-translational modifications that a 
protein requires for proper folding. 
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4.1.5. Binding studies with the intein-ficolin-B fusion protein to chitin 
It was theoretically possible that the intein-ficolin-B fusion protein loaded onto the chitin 
column would be properly cleaved, but that the ficolin-B itself would re-bind to the chitin by its 
carbohydrate recognition site. Therefore, I wanted to check the binding efficiency of 
recombinant ficolin-B from E.coli BL21 (DE3) pLysS cells. All ficolins bind to GlcNac (Teh et 
al., 2000, Matsushita et al., 1996). The molecular basis of this binding has been shown by X-
ray crystallography (Garlatti et al., 2007a, 2007b; Tanio et al., 2007). The cell wall analysis of 
A. fumigates has shown that chitin, mannans glycoproteins, and importantly β-1, 3-glucan is 
extensively distributed on the surface of the fungus (Goldman et al., 1999, Bowmann et al., 
2006). Recent studies have shown that L-ficolin binds to β-1, 3-glucan of A. fumigates and 
the binding was not significantly affected by EDTA (Garred et al., 2009). 
I tested the IPTG-induced crude bacterial lysates of E.coli cells that had been transformed 
with the vector containing the ficolin-B insert for their ability to bind GLcNAc agarose or 
chitin.  But no binding activity was observed (data not shown). This might be due to the 
improper folding of proteins leading to inclusion bodies. Tanio et al., 2009 has shown that 
multimerization of ficolins is important for effective biological activity and here in this case 
may not happen in E.coli. 
Since no binding activity could be observed with the E.coli lysate, in collaboration with Katja 
Hunold, we tested the binding activity to chitin and A.fumigatis with the DS2-expressed 
ficolin-B. The binding studies showed (Fig 3.14) that there was an increased binding to chitin 
with increasing concentration of ficolin-B independently of Ca2+. EDTA had no significant 
effect on ficolin-B binding to chitin beads.  The binding of ficolin-B to A.fumigatis needs to be 
tested further. 
Therefore it can be concluded that with the IMPACT kit system, polypeptides of ficolin-B 
might be expressed under denaturing conditions but these aggregate and make the intein 
system useless for ficolin-B purification. 
4.1.6. Protein expression in other vector systems 
Since we had problems in the expression and purification of ficolin-B with the IMPACT kit 
system, the next step was to test ficolin-B expression in E.coli with different vectors. As a first 
step we chose a His-tagged vector system as target proteins can be purified by immobilized 
metal affinity chromatography (IMAC) and immunodedected with His-tagged antibodies. 
Erickson et al., (1997) previously reported the His-tagged purification of the fibrinogen 
domain of ficolin protein. About 40% of the ficolin fibrinogen was recovered in the soluble 
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supernatant. However the protein was bound to the Q column and could not be eluted as it 
gets aggregated.  
Here I tried to express the full length ficolin-B protein with N- or C-terminal His-tags as I was 
not sure which tag will facilitate better expression of the protein. It was also observed that the 
molecular weights of the His-tagged ficolin-B (Fig. 3.16) were slightly higher (~37kDa). This 
difference was expected and is due to the presence of the His-tag at the N- or C-terminal end 
of the protein (approximately 3.6kDa). However the expression was again shown to be only 
in the insoluble fraction. 
As a next step I chose a GST-tagged vector system, since the use of GST as a fusion tag is 
desirable because it can act as a chaperone to facilitate protein folding, and frequently the 
fusion protein can be expressed as a soluble protein (Rancour et al., 2010). We used the 
pGEX4T1-NTEV vector which has a TEV-cleavage site. As TEV-protease is His-tagged we 
can easily remove it after cleavage by Ni-NTA agarose. The advantage of TEV is its specifity 
and that the cleavage efficiency is not much altered by salt or temperature. The full length 
ficolin-B coding sequence was cloned (Fig 3.18) and expressed (Fig 3.19) in E.coli cells. But 
again ficolin-B was expressed as an insoluble protein. The next step was to express the N-
terminal collagen domain of ficolin-B as an individual protein. Girija et al., 2007 have shown 
the gene sequence alignment of ficolins and mannose binding lectin (MBL) and had shown 
the presence of the putative MASP binding motif within the N-terminal collagen domain of 
ficolin. I cloned (Fig 3.20) and expressed (Fig 3.21) the N-terminal domain of ficolin-B. The 
resulting fusion protein had an expected calculated molecular weight of (~31kDa) along with 
the GST- protein (26 kDa). We were now able to express the N-terminal domain of ficolin-B 
in fusion with GST in a soluble form. This could be further purified in large scale and tested 
for its biological activity by protein interaction studies with MASP-2. This would help us to 
know whether multimerization is important for biological activity. 
Therefore it can be concluded from the different expression vector systems shown that full-
length ficolin-B cannot be expressed in the soluble form in E.coli and this might be due to its 
complex higher oligomer and multimer structure. In addition, protein conformation might 
dependent on glycosylation which cannot happen in E. coli. 
4.2. Mutational analysis of the ficolin-B specificity and biological function 
This part of the experimental research was aimed to know the mutational sensitive sites on 
ficolin-B for its effective biological functions. Since I was unable to express and purify ficolin-
B from E.coli cells, we decided to do this set of experiments with the ficolin-B expressed in 
the DS2 cell system, which is already an established system in our lab. Recent point 
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mutational studies have revealed the essential role of Lys55 in the collagenous region of MBL 
in the interaction with the MASPs and calreticulin (CRT) (M. Lacroix et al., 2009).  Endo et 
al., 2007 showed that the mouse ficolin-B cannot activate the complement system and this 
may be due to this single amino acid shift (alanine or methionine replaced by glutamic acid in 
the case of ficolin-B). Girija et al., 2011 provided the proof for the lack of complement activity 
of mouse ficolin-B being due to the glutamate residue in place of the usual 
aliphatic/hydrophobic residue in the MASP-binding site. Substitution of the glutamate for the 
aliphatic alanine residue in rat ficolin-B completely abolished MASP-binding and complement 
activation, so the acidic residue is particularly disruptive within the ficolin-B which might 
disturb complement activation.  
I undertook to mutate the glutamic acid of ficolin-B lack to alanine and see if this could lead 
to MASP2-binding and activation of the complement system. The mutants were constructed 
by the the QuickChange Site-directed Mutagenesis kit (Stratagene) to be tested for biological 
effects. Weak adjacent sites may enhance or decrease binding affinity and mutants will help 
to find these difficulties in fine specificity. Recent work by Cymer et al 2010 has shown that a 
single glutamate residue controls the oligomerization, function, and stability of the 
aquaglyceroporin GlpF. 
4.2.1. Production of recombinant wild type ficolin-B and mutants 
I expressed and purified the recombinant wild type ficolin-B and the mutant in the DS2 
expression system. In our lab, we have the DS2 expression system which utilizes a co-
transfection for generation of stably transfected S2 cell lines producing high quantities of 
recombinant mouse ficolin-B. But the draw back with this method was to get more positive 
clones during selection with hygromycin. So I cloned the wild type ficolin-B and the mutant 
gene in a fusion vector (pMT-pCoHygro) (Fig 3.23) that will allow for single transfection for 
production of more positive clones.  
4.2.2. Functional characterization of wild type ficolin-B and mutant ficolin-B 
Protein biochemical and chromatographic studies were used to characterise the protein. First 
I checked for the oligomerization of ficolin-B proteins by SDS-PAGE and gel filtration. 
Ficolins are highly oligomeric proteins with inter- and intra-chain disulfide bridges (Erickson 
et al., 1997) and multimerization is important for the protein to be biologically active (Tanio et 
al., 2007: Garlatti et al., 2009). I found that the mouse ficolin-B migrated as two bands on the 
SDS-PAGE reducing gel (10%) with an apparent molecular mass of 35 and 36 kDa (Fig. 3.24 
A), both of which are greater than the molecular mass of 34 kDa calculated from the amino 
acid sequence. This was in agreement with the recently published data on rat ficolin-B (Girija 
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et al., 2010). The reason for the double bands in SDS-PAGE is due to the difference in the 
glycosylation which was also observed for recombinant pig ficolin-α expressed in a 
mammalian system (Ohashi and Erickson, 2004). Girija et al., 2010 has reported that the 
double bands seen in SDS-PAGE is due to the fact that there is one potential N-linked 
glycosylation site in the fibrinogen  domain  and  five  potential  O-linked  sites  in  the 
collagen-like domain. So the two species observed on gels probably reflect different 
glycoforms. Under non-reducing conditions, ficolin-B migrated as mixture of polymers on 
SDS-PAGE (10%) gel consisting of more than 8 to 10 chains (Fig 3.24 B). 
Next I tested for the oligomerization and stability for ficolin-B in gel filtration. Here I used, “Old 
ficolin-B” (ficolin-B which was prepared a year before) and “Fresh ficolin-B” which was 
prepared just before the experiments. With “fresh ficolin B” we observed several overlapping 
peaks from the gel filtration column, indicating the presence of different oligomeric forms 
(subsequently called monomer or tetramer of subunits). With “Old ficolin-B” only trace 
amounts on monomers were observed. Oligomers were identified by comparison with the 
elution positions of the marker run. The results (Fig 3.25) indicate that the polypeptide (11-
13) formed a  complex by self-association with an apparent molecular mass of more than 
190  kDa,  most  likely  representing  tri-  or  tetramers  rather  than  dimers,  whereas  the 
polypeptide (15-17) migrated with an apparent mass less than 40 kDa, suggesting a 
monomer. Each of the eluted fractions was tested in Western blot for ficolin-B using the 
rabbit anti ficolin-B antiserum, however, the antibodies did not detect any ficolin-B. The 
protein content was probably too low (at background levels with the elution profile). The 
profile indicated only slightly that there might be a protein eluting within the molecular weight 
range of ficolin-B.  
Girija et al., (2011) also reported that the rat ficolin-B eluted as several overlapping peaks 
from a gel filtration column, indicating the presence of different oligomeric forms. They 
identified two major oligomers consisting of six and nine polypeptides (subsequently called 
dimers and trimers of subunits), together with smaller amounts of monomers and tetramers 
of subunits. Trace amounts of even larger oligomers were observed, probably comprising 
pentamers and/or hexamers of subunits. They used the eukaryotic expression system for 
protein production. In our case, I could not detect higher oligomers and this might be due to 
the difference in post translational modifications in the DS2 system. 
The expression of wild type and mutant ficolin-B expression is still going on. Therefore, in 
collaboration with Katja Hunold, I was only able to do the intial characterization of the protein 
regarding size and biological avtivity using DS2- expressed mutant ficolin-B supernatant. We 
tested for the mutant in supernatant for wild type ficolin-B characteristics in dot blot, Western 
blot and ELISA. The dot blot (Fig. 3.26) confirmed equally the presence of wild type and 
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mutant ficolin-B and the Western blot showed that there was no difference in oligomerization 
between the two proteins (Fig 3.27). Binding studies show that ficolin-B binds to GlcNAc and 
GalNAc (Endo et al., 2005). As already described above, we tested the mutant and wild type 
ficolin-B binding activity for AcBSA in ELISA (Fig 3.28). We found that there was not much 
difference in the binding activity between the two proteins and this may be due to the fact 
that the fibrinogen-like domains of ficolin is responsible for carbohydrate and pathogen 
recognition which is not affected by the mutation. X-ray crystallography studies on ficolins 
had demonstrated the molecular basis of GlcNAc-recognition in the fibrinogen-like domains 
(Garlatti et al., 2007a, 2007b; Tanio et al., 2007). The most interesting functional study will be 
the MASP-2 binding and C4 deposition assay since it is required for activation of the 
complement system.  
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5. Conclusion and perspectives 
Expression and purification of ficolin-B in the E.coli system was not possible because of 
formation of high oligomeric complex due to inter- and intra-chain disulfide bridges. With the 
DS2-expressed ficolin-B, some preliminary biochemical characterization was performed. The 
DS2-expressed recombinant ficolin-B was shown to be at least a trimer by gel filtration 
analysis, which is a low oligomeric form possibly due to the posttranslational modifications 
differing from other mammalian expression systems. Multimerization of ficolins is important 
for the protein to be biologically active. The use of an eukaryotic expression system will allow 
to produce proteins with the right glycosylations and posttranslational modifications. The wild 
type and mutant DS2-expressed ficolin-B will be tested for their oligomeric confirmation, 
complex formation with MASPs and subsequent C4 cleavage activity. It will be interesting to 
do mass spectrometry analysis of the recombinant proteins to know the details on the 
glycosylation motifs and potential glycosylation sites in the ficolin-B protein. In addition, 
Glycan array screening could be performed to know binding specificities for a broad screen 
of endogenous and exogenous carbohydrates (Emory glycomics lab, US. 
http://www.functionalglycomics.org/). This will provide a detailes insight into the binding 
affinities and possible function for ficolin-B.  
It will also be interesting to know the effect of the single amino acid mutational change 
(Glutamate to Alanine) in the collagen domain (which differs from other ficolins) of ficolin-B. 
The mutant ficolin-B can be used for comparision with wild type ficolin-B in respect to the 
strength of interaction with MASP-2 by surface Plasmon resonance (SPR). C4-deposition 
assay will let us know the binding intensity with MASPs and activation capacity for the 
complement pathway. In the lectin pathway, upon binding of the lectin-MASPs complexes to 
carbohydrates on the surface of pathogens, MASPs are activated to acquire proteolytic 
activity for the complement components C4 and C2, resulting in the elimination of pathogens 
after a chain reaction of proteolysis of complement components and protein assembly. It was 
recently reported that MBL activates complement component C3 without involvement of C2, 
implying that it also activates the alternative pathway (Selander et al., 2006). It would be 
intresting then to know a possible function for ficolin-B in the alternative pathway (Figure 5.1). 
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APPENDIX 
Appendix - I - Abbreviations and acronyms 
#                                       Number  
∆  heat aggregated  
A
x
 absorbance at a wavelength of x nm  
aa  amino acid  
Amp
R
 ampicilin resistance cassette  
AP  alkaline phosphatase or alternative pathway  
APS  ammonium persulphate  
bp  base pairs  
CBD  Chitin binding domain 
cDNA  complementary DNA  
CP  classical pathway  
DEPC-H
2
O  diethylpyrocarbonated water  
DES  Drosophila melanogaster expression system  
DNA  deoxyribonucleic acid  
dATP = A  deoxyadenosine triphosphate  
dCTP = C deoxycytidine triphosphate  
dGTP = G  deoxyguanosine triphosphate  
DMEM medium  Dulbecco's Modified Eagle Medium  
DMSO Dimethyl sulfoxide 
dNTP  deoxyribonucleotide  
dTTP = T  deoxythymidine triphosphate  
DTT  dithiothreitol  
ECL  enhanced chemiluminiscence  
EDTA  ethylenediaminetetraacetic acid  
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ELISA  enzyme linked immunosorbant assay  
FACS  fluorescence activated cell sorter  
fbg  fibrinogen  
FCS  fetal calf serum  
g  grams  
gDNA  genomic DNA  
GlcNAc N-acetyl-D-glucosamine  
GPC  gel permeation chromatography  
GST Glutathione –S-transferase 
H2O2 destilled water  
His  histidin  
HPLC High-performance liquid chromatography 
HRP  horseradish peroxidase  
HSA  human serum albumin  
Ig  immunoglobulin  
IMAC  ion-metal affinity chromatography  
IMP  inosine monophosphate  
IPTG  isopropyl-β-D-thiogalactoside  
kb  kilobases  
kD  kilodalton  
LB medium     Luria Bertani medium  
LP  lectin pathway  
LPS  lipopolysaccharyde  
mAb  monoclonal antibody  
Mb  megabases  
MCS  multiple cloning site  
min  minutes  
ml millilitre 
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mM millimolar 
μM micromolar 
M molar 
MP millipore water 
mRNA  messanger RNA  
MurNAc  N-acetylmuramic acid  
MW  molecular weight  
MWCO molecular weight cut off 
Ni-NTA nickel-nitrilotriacetic acid  
NTA  2-naphthoyltrifluoracetate  
OD  optical density  
ORF  open reading frame  
PAA  polyacrylamide  
PBS  phosphate buffered saline  
PCR  polymerase chain reaction  
PECs  peritoneal exudate cells  
Pen/Strep  penicillin/streptomycin  
PMNs  polymorphonuclear cells  
PMSF  phenylmethylsulphonylfluoride  
PVDF  polyvinylidene fluoride  
RBCs  red blood cells  
RIPA buffer  radioimmunoprecipitation buffer  
RNA  ribonucleic acid  
RT  room temperature  
RT-PCR  retrotranscription PCR  
S2  Drosophila Schneider-2 cells  
sec  seconds  
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SAP  shrimp alkaline phosphatase  
SDS  sodium dodecylsulphate  
SDS-PAGE  SDS polyacrylamide gel electrophoresis  
SP-A  surfactant protein A  
SP-D  surfactant protein D  
SPR surface plasmon resonance 
TAE buffer  Tris acetate EDTA electrophoresis buffer  
TBE buffer  Tris borate EDTA electrophoresis buffer  
TBS  Tris buffered saline  
TE buffer  Tris EDTA buffer  
TEMED  N,N,N’,N’-Tetramethylethylendiamin  
TK  thymidine kinase  
TOPO  tri-o-octylphosphine oxide  
TRITC  tetramethyl rhodamine isothiocyanate  
Tween  Tween 20  
U  units  
vol  volume(s)  
WB  Western Blot  
wt  wildtype  
X-gal  5-bromo-4-chloro-3-indolyl-ß-D-galactoside  
°C degree celcius 
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Appendix – III – Construct overview 
 
Construct 
 
 
Description 
 
 
Restriction sites 
 
Purpose 
 
pTXB1 
 
 
Intein tag 
 
SapI / NdeI 
 
E.coli expression 
and purification 
 
pET28a 
 
 
N-terminal His tag 
 
BamHI / XhoI 
 
E.coli expression 
 
pProEXhtb 
 
 
C-terminal His tag 
 
BamHI / XhoI 
 
E.coli expression 
 
pGEX-4T-1 
 
 
GST tag 
 
BamHI / XhoI 
 
E.coli expression 
 
pGEX-4T-N-TEV 
 
 
GST and His tag 
 
NdeI / XhoI 
 
E.coli expression 
 
pMT-Bip-V5-Hygro 
 
V5 His tag NarI / PmeI 
 
DS2 cell 
expression 
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